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ABSTRACT OF DISSERTATION 
 
 
TARGETING THE CELLULAR REDOX ENVIRONMENT: A NOVEL APPROACH 
FOR THE TREATMENT OF HEMATOPOIETIC NEOPLASMS 
Hematopoietic stem cells (HSCs) that function to maintain the hematopoietic 
compartment through self-renewal and differentiation capacities, as well as their 
downstream progeny, are susceptible to transformation resulting in the generation of the 
leukemic stem cell (LSC). Chief in the factors that control HSC regulation and protection 
of the HSC compartment is the cellular redox environment. Deregulation of the 
Hematopoietic Stem/Progenitor Cell (HSPC) redox environment results in loss of HSPC 
function and exhaustion. The characteristic developments of HSPC exhaustion via 
exposure to redox stress closely mirror phenotypic traits of hematopoietic malignancies, 
presenting the HSPC/LSC redox environment as a potential therapeutic target. While 
myelosuppression and HSPC exhaustion are detrimental side effects of classical 
chemotherapies, new approaches that differentially modify the HSPC/LSC redox 
environment may demonstrate LSC cytotoxicity while offering protection of normal HSPC 
function via differential activation of internal signaling pathways. Precisely how the redox 
environment and downstream signaling events are affected by these treatments remains 
unclear; thus highlighting the need for robust methods that evaluate the HSPC/LSC redox 
state. Because the glutathione (GSH), glutathione disulfide (GSSG) redox couple heavily 
contributes to the management of HSPC function and redox environment, characterizing 
the GSH/GSSG redox potential at the HSPC level would provide great insight for 
therapeutic opportunities. However, accurate measurement the GSH/GSSG redox potential 
within HSPCs/LSCs has been difficult due to their inherently low numbers. Here, we 
describe the development and validation of a sensitive method used for the direct and 
simultaneous quantitation of both oxidized and reduced GSH via LC-MS/MS. We use these 
methodologies to establish a difference in GSH-GSSG half-cell reduction potentials 
between normal and malignant HSPCs and examine the therapeutic effect of a redox active 
MnSOD mimetic, Mn(III) mesotetrakis (N-n-butoxyethylpyridinium-2yl) porphyrin, 
MnTnBuOE-2-PyP5+ (MnP), within these populations in vitro as well as within a human 
xenograft model in vivo. MnP demonstrates significant cytotoxic effects in several 
 
malignant models, while inducing an opposite cytoprotective effect in normal HSPC 
populations. The GSH/GSSG redox balance, specifically managed by glutathione 
reductase activity, is identified as a determining factor of MnP efficacy in various 
malignant populations. Treatment of the human myelodysplastic cell line (MDSL) offers 
mechanistic insights into MnP efficacy through hydrogen peroxide mediated activation of 
activator protein 1 (AP-1) signaling. We identify the redox dependent activation of JunB, 
a known regulator of normal myeloid lineage HSC proliferation, as a transcriptional 
mechanistic mediator of MnP treatment induced AP-1 signaling resulting in malignant 
cytotoxicity. The development of this novel method allowing for the identification of 
targetable differences between normal and malignant cell populations has provided insight 
to the underpinnings of potential redox based therapies. Additionally, the finding that MnP 
can target varying cellular redox states and exert selective cytotoxicity in malignant over 
normal populations by re-gaining lost control of AP-1 signaling demonstrates the potential 
for development of safe therapeutics within a variety of clinical applications. 
 
Key Terms: Hematopoietic Stem Cell, Cellular Redox State, Glutathione, JunB, MDS, 
Chemoresistance 
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Chapter One: Redox Active Compounds in Normal and Malignant Hematopoietic 
Stem Cells. 
Introduction  
The hematopoietic compartment contains a tightly regulated hierarchy of cell types 
responsible for the function and maintenance of the bone marrow and blood systems. All 
peripheral blood cells, both the myeloid and lymphoid lineage, differentiate from a 
common pool of hematopoietic stem and progenitor cells (HSPCs) which reside within 
the bone marrow (74, 198). This pool of HSPCs can be broken down into three subsets of 
cell types: the long-term hematopoietic stem cell (LT-HSC), short term hematopoietic 
stem cell (ST-HSPC), and the multipotent progenitor cell (MPP). Two distinct progenitor 
cell populations emerge from the MPP pool: the common lymphoid progenitors (CLPs) 
and common myeloid progenitors (CMPs). Differentiation from these progenitor cell 
populations eventually results in the establishment of peripheral effector cell populations 
within each lineage, such as B and T cells within the lymphoid lineage or erythrocytes 
and neutrophils within the myeloid lineage (1, 74, 199). There are several phenotypic and 
functional facets that define the HSPC populations individually and as a whole. The 
central defining characteristics of hematopoietic stem cells, particularly those within the 
long-term population, are the ability to self-renew while, at the same time, limit the size 
of the HSPC population and demonstrate the potential to differentiate into any mature 
cell type within the hematopoietic system (Figure 1.1) (1, 16, 74, 131, 198, 199).      
Short-term hematopoietic stem and progenitor (ST-HSPC) populations have the capacity 
to maintain normal hematopoiesis for a period of 6 to 8 weeks. Serial transplant studies in 
vivo have identified the long-term hematopoietic stem cell (LT-HSC) as the population 
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and cell type which can sustain normal hematopoiesis throughout an organism’s entire 
lifespan. This fact demonstrates a loss of HSC self-renewal capacity as a function of 
increased cellular differentiation. For these reasons, normal LT-HSC function must be 
maintained throughout the lifespan of an organism. This elucidates the LT-HSCs as the 
only population that holds true characteristics of the hematopoietic stem cell (HSC). 
Because self-renewal and differentiation of long-term and short-term hematopoietic stem 
and multipotent progenitor cell populations is essential to normal hematopoietic function, 
we define this entire population as the hematopoietic stem/progenitor cells (HSPCs) and 
reserve the term HSC for the true LT-HSC populations.  
Loss of normal LT-HSC and ST-HSPC function is a hallmark of natural stem cell aging 
and several hematopoietic disorders, most notably the development and progression of 
hematopoietic malignancies (1, 6, 16, 74, 86, 120, 131, 198, 199, 223, 233, 248). Within 
these cancers, normal hematopoietic regulation is lost, yet disease still progresses through 
the differentiation and clonal expansion of progenitor cell pools eventually leading to a 
lack of terminal differentiation to functional cell types within the periphery. This 
observation led to the identification of the cancer stem cell (CSC) or more specifically, the 
leukemic stem cell (LSC) (4, 86, 87, 167, 186, 190, 204, 223, 248). Although we know that 
hematopoietic neoplasms are driven by LSC populations, developing therapies that treat 
LSC pools as entities separate from normal HSPCs has been difficult. Thus, little progress 
has been made in the development of therapies that both eradicate malignant HSPCs while, 
at the same time, protect or pose no detriment to healthy HSPC populations within a single 
patient.  
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There is a heterogeneous and diverse set of cytogenetic abnormalities within various 
hematopoietic cancers that, in some cases, may lend themselves to personalized treatment 
plans. However, intrinsic characteristics that separate normal HSPCs from their 
malignant counter parts are becoming more relevant (11, 17, 18, 24, 102, 146, 172, 216). 
The identification of these differences will lead to the development of safe therapeutics 
that have broad implications for treatment of several hematopoietic neoplasms across 
patient populations. Chief in the differences between normal and malignant HSPCs is the 
generation of reactive species and the management of the cellular redox environment (8, 
33, 88, 100, 110, 147, 148, 167, 186, 189, 204, 216, 221, 226). It has been well 
established that cancer cells demonstrate elevated levels of reactive species generation 
and a difference in basal redox environment as compared to their normal counter parts. 
This difference is heavily rooted in an increased metabolism and production of reactive 
oxidative species such as superoxide and hydrogen peroxide, which in turn, leans on the 
cellular antioxidant capacity and thus, enhances the need for reducing species such as 
glutathione (GSH). The result is an unbalance in equilibria that stresses both sides of 
cellular oxido-reduction capacity, herein we refer to this stress imbalance simply as redox 
stress. In fact, the malignant hematopoietic phenotype mirrors the changes in normal 
hematopoietic architecture brought on by increased production of redox stress, which 
results in alterations to the HSPC redox environment (87, 90, 92, 165, 189, 221). This 
fact has recently presented researchers with a druggable target in which a therapeutic 
index can be defined that exploits the malignant cell redox environment while leaving 
normal cell populations unharmed (88). This is accomplished by examining the effects of 
redox active compounds in both normal and malignant hematopoietic stem and 
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progenitor cell populations. Redox active compounds have traditionally been defined as 
those which can undergo single electron transfers acting as either an oxidizing or 
reducing agent. These compounds include nitroxides such as Tempol, flavonoids such as 
oxorylin or baicalein, and those with transition metal centers, such as Mn (III) meso-
tetrakis(N-(n-butoxyethyl)pyridinium-2-yl) porphyrin (MnTnBuOE), capable of cycling 
through multiple oxidation states acting as active sites for therapeutic efficacy (12-14, 67, 
160, 210, 211, 229, 232, 252). Other compounds, such as doxorubicin, may transition 
through structural changes as a result of electron exchange via metabolism (47, 50, 68, 
114, 135, 136, 246). Additionally, we consider those compounds that affect the cellular 
redox environment by actively modifying concentrations of cellular reductants or those 
which inhibit normal antioxidant enzyme function, such as Buthionine Sulfoximine 
(BSO) or Parthenolide (PTL), although actual oxido-reduction reactions do not directly 
result from the chemistry of the molecules themselves (90, 163). In this review, we offer 
a concise summary of key studies examining the effects of endogenous mechanisms and 
redox active compounds resulting in changes to the cellular redox environment of normal 
and malignant HSPCs. Furthermore, we present the HSPC cellular redox environment as 
a druggable target that allows for effective intervention within malignant populations 
while leaving normal HSPC populations unharmed. 
Redox Regulation and Redox Active Compounds Affect in Normal HSC Function 
The production and elimination of the initial and ensuing reactive species are the 
cornerstones of cellular redox environment management. Here, metabolic byproducts 
such as O2
.- (superoxide) and H2O2 (hydrogen peroxide), as well as 
.
OH (hydroxyl 
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radical), and ONOO- (peroxynitrite) are the main reactive species responsible for 
oxidative damage, including DNA oxidation, lipid peroxidation, and protein oxidation as 
well as nitration (221). As a result, an increase in metabolic activity and reactive species 
generation is closely associated with an increase in cellular proliferation and 
differentiation (92, 165, 198, 219). It should come as no surprise then that varying 
concentrations of the original redox active compound, molecular oxygen (O2), 
significantly affects cellular redox status and HSPC proliferation. The bone marrow 
niche, or extracellular components surrounding HSPCs, and peripheral tissues have 
oxygen tensions ranging from 1-7%. In vitro study of primary normal and malignant 
HSPCs, as well as various culture lines, has demonstrated the beneficial effects of a 
hypoxic environment (28, 37, 38, 80, 81, 191, 194). Both normal and malignant HSCs 
benefit from growth conditions that have oxygen concentrations ranging from 1-3%, 
compared to cultures at normoxic (5%) and atmospheric (21%) O2 concentrations  (40, 
92, 164, 205, 218). Interestingly, a low oxygen environment leads to a decrease of 
glutathione levels, as well as antioxidant enzyme expression and function (29, 57, 149). 
Primitive HSC populations have been thought to be refractory to induction of oxidative 
stress, due to their quiescent state, antioxidant capacity, and local niche environment. 
However, their environment may be a key factor in keeping HSCs sensitive to redox 
stress. This facet of the bone marrow environment has potential in allowing for the 
development of differential sensitivities to redox insult between normal and malignant 
HSC as well as HSPC populations (Figure 1.2). 
CD34+ HSPCs express higher levels of superoxide dismutase (SOD1 and SOD2) and 
Catalase (CAT) relative to other antioxidant enzymes, such as, glutathione peroxidases 
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(GPx), glutathione-S-transferases (GSTs), glutathione reductase (GR), thioredoxin (TXN) 
and thioredoxin reductase (TXNR) utilized for the removal of hydrogen peroxide as well 
as other radicals and reactive species (Figure 1.3) (163). However, the expression level of 
antioxidant defense enzymes such as SOD and CAT is lower in the primitive LT-HSC 
compartment in comparison to their downstream differentiated progeny (6, 134, 221). 
This means that if these defense enzymes fail, a significant buildup of primary and 
secondary reactive species may occur, thus, quickly and, potentially irreversibly, altering 
the redox environment within HSCs. Additionally, hematopoietic malignancies are 
generally typified by the uncontrolled clonal expansion of HSPC populations. Therefore, 
primitive malignant populations may, themselves, express low levels of antioxidant 
enzymes, such as SOD or catalase. This would then result in higher levels of downstream 
reducing agents such as the GSH/GSSH redox couple. 
In the past decade, several key studies have identified management of the HSPC redox 
environment as a crucial factor in the maintenance of the HSPC population. The HSPC 
compartment itself contains cell populations that can be separated based on their ROS 
levels and redox environments. Using 2’-7’-dichlorofluorescence diacetate (DCF-DA), 
Jang and co-workers were able to separate two HSPC populations characterized by high 
and low levels of ROS (92).  These two populations display distinct differences in HSPC 
function. Limiting dilution transplantation assays showed that HSPCs with low levels of 
ROS repopulated recipient mice significantly better than HSCs with high levels of ROS. 
This characteristic was also carried over to secondary and tertiary transplant recipients. 
Additionally, the ROS low population contained more primitive long-term culture-
initiating cells (LTC-ICs) and resulted in better multilineage reconstitution (92). 
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Interestingly, upon transplantation the ROS high population resulted in lineage 
reconstitution that favored elevated myeloid development. Conversely, ROS low cells 
favored lymphoid lineage development. This indicates a potential for the development of 
myeloid lineage malignancies upon redox deregulation within the normal HSPC 
populations. The ROS high population demonstrated elevated levels of p38 activity, 
elevated expression of p16 and lower levels of p53 expression. The LTC-IC capacity of 
the ROS high population did respond to treatment with either a p38 MAPK inhibitor, the 
GSH precursor N-acetyl-L-cysteine (NAC), or Rapamycin (92). This indicates that 
buffering the HSPC redox environment can improve normal HSPC function. Thus, as one 
might expect, NAC treatment aids the engraftment of normal human HSPCs isolated 
from human cord blood into recipient mice. These results are demonstrated even in the 
highly-enriched Lin- CD34+ CD38- CD90+ CD45RA+ CD49f+ Rholow HSC population 
indicating exogenous protection against reactive species challenge and can independently 
improve HSC function (85). 
In 2007, Ito and colleagues utilized the Atm -/- mouse model to demonstrate that an 
elevation of ROS activated p38 MAPK signaling, resulting in a loss of normal HSC 
maintenance as well as quiescence eventually leading to HSPC senescence (90). They 
found that depletion of cellular glutathione (GSH) via buthionine sulfoximine (BSO) 
treatment lead to an increase in H2O2 within the HSPC Lin
-/ Sca-1+/c-Kit+ (LSK) 
population resulting in an increased expression of cell cycle regulators p15INK4B p16INK4A, 
p18INK4C, and p19ARF. This lead to a loss of HSPC function; yet the upregulation of tumor 
suppressor proteins was reversed by treatment with NAC or a p38 MAPK inhibitor. 
These effects were not demonstrated in differentiated cell populations (90). Similarly, 
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ROS accumulation, p15INK4B, p16INK4A, p18INK4C, and p19ARF upregulation and loss of 
HSPC function were demonstrated in Atm -/- mice. Within this model, treatment with a 
p38 MAPK inhibitor both before and after transplant recovered HSC function in Atm -/- 
mice, compared to wild type controls. Using NAC and p38 MAPK inhibitor treatments, 
this study also demonstrated that ROS mediated p38 activation is responsible for a loss of 
HSPC quiescence (90). Interestingly, hydrogen peroxide oxidation of ATM results in 
internal disulfide crosslinking and dimer formation that leads directly to ATM activation 
independent of DNA double strand breaks (78). Results found by Ito and colleagues are 
very similar to those found by Myamoto and colleagues using a Foxo3a-/- mouse model. 
These studies demonstrate FOXO3A regulation of HSC function. Importantly FOXO3A 
operates downstream of PTEN/PI3K/AKT pathway, and loss of FOXO3A activity results 
in HSC exhaustion and activation of the p38 MAPK pathway (137). 
Just as these phenomena have been demonstrated in mice, human cells subject to serial 
transplantation in mice demonstrate similar characteristics. Serial transplantation of 
human Lin- CD34+ CD38- HSCs lose their ability to repopulate the bone marrow (245). 
This loss of HSC function in human cells is accompanied by an accumulation of 
oxidative DNA damage, characterized by an increase in γH2AX foci, as well as an 
increase in the expression of cell cycle inhibitors p16INK4A, p14ARF, and p21CIP (245).  
The formation of these DNA damage foci are recapitulated in normal human HSCs 
treated with BSO. Upon formation, DNA damage repair enzymes, ATM, p53 binding 
protein (53BP1), CHK2, and FOXO3A are recruited to these DNA damage foci. 
Furthermore, examination of the highly-enriched Lin- CD34+ CD38- CD90+ CD45RA+ 
HSC population showed that although damage is seen in both the stem and progenitor 
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cell (CD34+ CD38+) populations, only the HSC compartment undergoes cell cycle arrest 
and apoptosis. Additionally, HSC populations recover more slowly than progenitor 
populations after the oxidative insult is removed. Consistent with other studies, addition 
of NAC as a protecting agent preserves HSC function in correlation with decreased 
accumulation of DNA damage foci, even in the face of oxidative insult (245). Control of 
DNA damage response can also be managed via the polycomb repressor (BMI1) 
signaling via control of INK4A/ARF (CHK2) proteins. A separate study indicates that 
loss of BMI1 function results in mitochondrial dysfunction and accumulation of ROS, 
and loss of HSPC self-renewal and differentiation, a phenotype that can be partially 
restored by treatment with NAC or the deletion of the Chk2 gene itself (121). 
Clearly the accumulation of oxidative damage incurs a detrimental effect on HSC 
function, and as one may anticipate, NRF2 activity has been identified as a major 
regulator of the HSC redox environment and HSC function (106, 132, 228). Tsai and 
colleagues used the Nrf2-/- mouse to demonstrate familiar effects on HSC function. These 
studies elegantly showed that the loss of NRF2 resulted in an increase in the Lin- sca-1+ 
c-kit+ (LSK) population, but only within the ST-HSC and MPP compartments, not within 
the LT-HSC population (219). Furthermore, Nrf2-/- mice demonstrated an increase in both 
the common myeloid, granulocyte-macrophage, megakaryocyte-erythroid (CMP, GMP, 
MEP) and lymphoid (LMPP, CLP-1, CLP-2) progenitor cell populations. Although 
progenitor pools underwent significant expansion, the primitive LT-HSC populations 
were unchanged. However, Ki-67 analysis, 5-FU pulse experiments, and culture in OP9-
DL1 revealed that NRF2 regulates HSPC proliferation and differentiation resulting in 
diminished quiescence and increased differentiation within the most primitive LT-HSC 
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populations (219). Importantly, NRF2 deficient HSPCs also significantly underperformed 
in colony formation and in vivo transplant assays indicating that not only does NRF2 
regulate proliferation and differentiation, but also regulates HSPC self-renewal and 
function. Proliferation analysis via co-culture of deficient cells with WT counterparts 
demonstrated a proliferative advantage for the Nrf2-/- cells (219). Chimeric studies 
showed that the proliferative advantage is generated from within the HSPC itself and 
does not result from signals received from the bone marrow environment. Moreover, the 
loss of NRF2 results in a decreased bone marrow homing effect implying that NRF2 even 
regulates the retention of HSPCs in bone marrow (219). This homing effect is linked to 
the loss of CXCR4 expression resulting in deficient chemotaxis abilities in Nrf2-/- HSPCs 
(60, 219). 
The studies discussed above have laid the groundwork for a clear understanding of how 
the HSPC redox environment affects normal HSPC regulation and function. Ultimately, 
dysregulation of HSPC redox balance results in well-defined changes to HSPC 
populations. As previously noted, the resulting alterations to HSPC populations mimic 
those demonstrated in several disease states; most notably, the myeloproliferative 
disorders. Clearly, regulating the cellular glutathione pool is required for faithful 
management of ROS and HSPC function. HSPCs that undergo redox deregulation 
resulting in an increase in ROS seem to demonstrate a natural response that functions 
through the p38 MAPK signaling as well as FOXO and ATM DNA damage response 
pathways (Figure 1.4) (90, 92, 137). This results in loss of HSPC quiescence and 
function. Despite the perception that HSPCs maintain robust function as a result of their 
protected location and their highly quiescent state, we now know that HSPCs not only 
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rely on intrinsic signaling but that HSPCs are more sensitive to redox stress than 
previously thought (245). These facets are highlighted by improving HSPC function 
through buffering redox capacity but also by the result of losing major regulatory control 
over redox environment management via transcription factors such as NRF2 (85, 219). 
Thus, redox modulators, such as BSO, which induce strong conditions of oxidative stress, 
work to the detriment of normal HSPC function. Conversely, compounds such as NAC 
that provide antioxidant aid, improve HSPC function.  
Chemotherapeutics and Normal HSCs 
The work summarized above demonstrates the importance of HSPC redox regulation in 
maintaining normal HSPC function. Normal HSPC toxicity and functional exhaustion is a 
significant problem underlying the use of traditional chemotherapeutics for the treatment 
of hematopoietic malignancies. Most chemotherapies currently utilized for the treatment 
of the hematopoietic malignancies are not designed to manipulate the cellular redox 
environment of the HSPC; rather, they target DNA synthesis or immune function. 
However, we now know that many cancer therapeutics do in fact impact the redox milieu 
of target and normal tissues. These redox active therapeutics impart detrimental effects 
on HSCs that echo the results previously discussed. Methotrexate (MTX), a long-
approved cancer drug within the antifolate class which inhibits endogenous nucleotide 
synthesis, has been well documented to induce oxidative stress within target tissues (9, 
202). MTX treatment results in an increase of superoxide production while concurrently 
depleting cellular glutathione and total thiol levels by 70%. These MTX mediated 
changes in the cellular redox environment are accomplished via inhibition of MnSOD, 
GPx, glutathione reductase (GR) and γ-glutamylcysteine synthetase (GCL) (9). While 
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chemotherapeutics such as MTX target dividing cells, quiescent HSC populations seem 
to remain refractory to MTX treatment even in the face of cell cycle inducers. However, 
inhibition of nucleoside transport allows for HSPC sensitization to MTX cytotoxicity 
resulting in a loss of HSPC function (5). Although antifolate drugs mainly target DNA 
synthesis, their effects on redox management cannot be ignored, particularly in the HSC 
population where glutathione metabolism and homeostasis is important. Similarly, 
cyclophosphamide, an agent that targets dividing cells via induction of DNA cross 
linking, causes a significant amount of reactive oxygen species production measured by 
DCF fluorescence in HSPCs. This leads to hematopoietic suppression demonstrated by 
loss of HSPC quiescence and function followed by increases in peripheral blood and 
splenic progenitor populations (143). This is typified by a significant decrease in the 
GSH/GSSG ratio. Interestingly, application of a glutathione disulfide mimetic 
significantly decreases the production of ROS and partially rescues the changes in 
cellular glutathione (49). This GSSG mimetic also increases the number of HSPCs 
depleted by cyclophosphamide treatment and partially rescues HSPC function. Treatment 
also rescues cyclophosphamide suppression of antioxidant gene expression, particularly 
SOD3 and GPX2 (49).  
Perhaps one of the most potent and popular chemotherapeutics approved for treatment of 
leukemia’s are the anthracyclines. Of this class, Doxorubicin/Adriamycin (DOX/ADR) is 
possibly the most well documented redox stress inducer. DNA intercalation and 
inhibition of topoisomerase II is the primary mechanism of DOX induced cytotoxicity in 
cancer. However, the ability to act as a redox modifier results from NADPH mediated 
formation of a semiquinone structure, which allows for the generation of oxygen radicals, 
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hydrogen peroxide, DNA damage, and alterations in bioenergetics (47, 50, 68, 114, 135, 
136, 246, 254). Fenton type chemistry may then exacerbate this process, leading to the 
generation of hydroxyl radicals. It is no surprise then that the use of anthracyclines such 
as doxorubicin is applied to the detriment of normal hematopoiesis (19, 39, 42). 
Traditionally, pharmacological doses of DOX induce myelosuppression, cardiac toxicity, 
and the enrichment of refractory cancer stem cells through the elevated expression of 
multidrug resistant proteins such as MDR1 and MRP1/ABCC1 (19). DOX treatment 
specifically suppresses the number of ABCG2+ HSPCs and bone marrow sphere 
formation in comparison to vehicle and Paclitaxel controls in vitro. Decreases in 
ABCG2+ HSPCs as well as peripheral white blood cells have also been demonstrated in 
vivo at doses of 1-5 mg/kg DOX (19). More recently, Mahbub and colleagues discovered 
that DOX  and etoposide (ETP) can be combined with several different polyphenol 
compounds to enhance malignant cell death in both lymphoid and myeloid lineage cancer 
models while at the same time protect normal CD34+ and CD133+ HSPC 
populations(126, 127). With DOX and ETP in vitro concentrations ranging from 0.1-0.4 
µM, combinations of five different polyphenol compounds (Quercetin, Apigenin, 
Emodin, Rhein, and Cis-stilbene) all recovered levels of ATP production and Caspase 3 
activity when compared to DOX and ETP treatment alone. In these studies, cellular 
glutathione levels were identified as a key factor in mediation of protection in 
combination treatments (126, 127). Interestingly, quercetin and apigenin, compounds 
recognized as mitocan’s (which specifically target mitochondria of cancerous cells) can 
bind ANT (adenine nucleotide translocase) of the mitochondrial permeability transition 
pore, inhibiting its function and the efflux of mitochondrial ATP (72, 153). 
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Redox-based Therapeutic Protection of the HSPC 
A precedent for HSPC protection has been established in the past with the use of 
granulocyte colony stimulating factor (G-CSF), erythropoietin, and other hematopoietic 
stimulants such as pegfilgrastim (Nulasta). These have been used to bolster production of 
peripheral blood cells in the face of small molecule chemotherapeutics, such as 
cyclophosphamide, as well as antibody based therapies (119). While the use of 
antioxidants, such as resveratrol and NAC, in cancer therapeutic regimens has been a 
subject of debate, the prospect of protecting normal HSPC function while killing 
malignant cells merits investigation and consideration, as the potential impact of 
accomplishing both simultaneously cannot be over stated. HSPC protection in the face of 
oxidative insult has been accomplished through the upregulation of antioxidant enzyme 
function. Furthermore, this protection is actually supported by the induction of redox 
stress, ( i.e., the generation of oxido-reductive reactive species that upregulate 
endogenous antioxidant machinery). Liposomal delivery of a vector containing an 
MnSOD construct protected HSPCs of mice receiving a limiting dose of donor bone 
marrow in the face of a 10 Gy total body irradiation (TBI) (134). This protective effect is 
enhanced when the MnSOD vector is delivered before the TBI. Protection of the HSPC is 
accompanied by a significant decrease in ROS production. Interestingly, HSCs 
overexpressing catalase (CAT) and MnSOD performed better in long term competitive 
repopulation assays, with CAT outperforming the MnSOD over expressers. Importantly, 
the repopulation ability of these subjects was significantly increased after recipients were 
exposed to a lower 2 Gy dose of radiation. This indicates that upregulation of antioxidant 
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defenses primes HSCs to rebuff subsequent oxidative insult, resulting in an increase in 
HSC function (134).  
The antioxidant protective effect of upregulated MnSOD in HSPCs can also be achieved 
through the application of manganese containing porphyrin compounds (12, 14, 211). A 
significant characteristic of these compounds is the stable Mn3+ center and the ability to 
accumulate in the mitochondrial fraction (193). Manganese, and iron containing 
porphyrins mimicking endogenous SOD function have been successfully utilized for the 
protection of bone marrow, among other tissues, against the oxidative challenges of 
radiation therapy (12, 31, 210, 211, 234). MnTE-2-PyP5+ (MnTE) has demonstrated 
protection of the HSPC in the face of a sub-lethal TBI dose of 6.5 Gy. Administered at a 
dose of 6 mg/kg on the day of and for 30 days subsequent to TBI injury, MnTE-2-PyP5+ 
improved hematopoietic recovery (12, 118, 211). This resulted from improved function 
of both hematopoietic stem and progenitor cells compared to control treated mice. 
Importantly, MnTE treated HSPCs demonstrated a decrease in senescence induced by 
TBI through the downregulation of p16Ink4a expression (161, 185, 231). Pharmacological 
protection of both the splenic and bone marrow HSPC compartments from TBI of 7.5 Gy 
has also been achieved through the implementation of the flavonoid, baicalein (160). 
Both in vitro and in vivo treatment with baicalein resulted in an inhibition of phosphatase 
MKP3, ERK activation, nuclear accumulation of NRF2 and an increase in NRF2 target 
mRNA (160). These studies indicate that redox active compounds may offer dual 
targeting of the NRF2 and MAPK signaling pathways in normal HSPCs, a concept that 
may aid redox active therapeutic targeting of malignant HSPC populations over normal 
HSPCs.  
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Our studies demonstrated similar effects of improved HSPC number and function 
generated by overexpression of mitochondrial MnSOD. Our more recent work has further 
explored this concept utilizing the MnSOD mimetic MnTnBuOE-2-PyP5+ (MnTnBuOE). 
MnTnBuOE treatment in vitro as well as chronic treatment in vivo results in an increase 
the HSPC LSK population, similar to MnSODTgH mice (256). Moreover, LSK 
populations significantly increase through tertiary bone marrow transplants from donor 
cells treated with MnTnBuOE for 16 hours in vitro as well as donor BM from mice 
treated at 2 mg/kg/ 3 times per week for a total of 60 days. Not only does MnTnBuOE 
increase HSPC function evidenced by long-term transplant studies, MnTnBuOE 
treatment significantly improves the recovery of RBC’s and hemoglobin after induced 
acute blood loss (256). Although MnTnBuOE is traditionally considered to function as an 
antioxidant, due to its MnSOD like activity, we found that MnTnBuOE treatment 
decreases mitochondrial function and ATP-linked oxygen consumption within the HSPC 
fraction. Concurrently, MnTnBuOE induces mild ROS production, measured by DCF 
fluorescence. Here, an increase in DCF fluorescence identifies an increase in general 
reactive species. This is presumably due to an increase in hydrogen peroxide production 
resulting from the reduction of superoxide by MnTnBuOE. However, because SOD 
mimetics are also known to modulate peroxynitrite levels, further study is required to 
elucidate the precise ROS resulting from MnTnBuOE treatment. Rather than oxidative 
activation of p38 MAPK signaling resulting in cellular senescence and apoptosis as 
previously mentioned, MnTnBuOE treatment results in the activation of ETS (E26 
Transformation Specific) and NRF2 transcriptional machinery. MnTnBuOE treatment 
results in an increase of NRF2 target transcript levels (CAT, MnSOD, GCLC, GCLM, 
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Nq01, UPC1, UPC3, and PRDXR1)(256). Western blot analysis of the LSK population 
confirms the increase of MnSOD, CAT, GSTp1, and UPC3 protein levels after 
MnTnBuOE treatment. These results indicate that MnTnBuOE initially acts as a transient 
pro-oxidant ultimately resulting in activation of an antioxidant phenotype that improves 
and protects HSPC function. In fact, we found that the HSPC/LSK population has a 
significantly higher 2GSH/GSSG ratio as well as an increased ability to remove hydrogen 
peroxide in comparison to differentiated myeloid progenitor cells (256).  
Protecting or supplementing HSPC function through the upregulation of antioxidant 
activity via gene delivery or chemotherapies is demonstrated by the application of 
limiting doses of sub-lethal and lethal TBI (12, 75, 118, 134, 161, 185, 231, 256). The 
management of NADPH/NADP+ levels has emerged as a critical factor for the protection 
of HSPC function. HSPCs express multiple isoforms of the nicotinamide adenine 
dinucleotide phosphate oxidases (NOX) that constantly produce ROS (166). TBI causes 
DNA damage and double strand breaks leading to the upregulation of the INK4A cell 
cycle regulators and HSPC senescence (185, 231). Inhibition of NOX by treatment with 
diphenylene iodonium (DPI) resulted in HSPC protection from ROS induced DNA 
damage(161). This is similar to the protection achieved by HSPC treatment with MnTE 
(118). As previously noted, MnTE treatment protects irradiated HSPC function by 
downregulation of p16INK4A, a key player in p38 MAPK induced HSPC senescence. 
MnTnBuOE treatment of non-irradiated HSPCs significantly improves HSPC function 
through the transient production of ROS and activation of NRF2. This results in 
upregulation of not only MnSOD and CAT protein levels, but also results in an increase 
NAD(P)H dehydrogenase quinone 1 (NQO1) transcript levels (256). Together, these 
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results indicate that the redox management of the NADPH/NADP+ system is critical 
HSPC regulation. This also presents the NOX and NADPH dehydrogenases as potential 
targets for redox active compounds that include the Mn porphyrins. Other, natural extract 
compounds such as apocynin and pumbagin also target the NOX system as well as 
modify the cellular redox environment through changing the cellular GSH concentrations 
(128). Thus, emerging redox active compounds with the ability to act not only as a mild 
antioxidant, but also as a mild pro-oxidant may not only be successful in eradicating 
malignant cells, but also may protect normal HSPC function. 
These studies further suggest that, contrary to the currently accepted dogma of ROS 
effects on long term HSC function, modulation of oxidative challenge to illicit a low to 
moderate level of redox stress can actually offer protection by upregulating HSPC 
function through NRF2 activation. This is accomplished through functional duality of 
redox-cycling compounds (Figure 1.4). For example, MnTnBuOE has the ability to 
oxidize superoxide to molecular oxygen in one half reaction while maintaining the same 
proclivity for the reduction of superoxide to hydrogen peroxide in another half reaction 
(12-14, 210, 211). Redox active compounds can accomplish this by closely mimicking 
structure-function characteristics of endogenous enzymes. In the case of MnTnBuOE, 
functional mimicry is characterized by the half-wave reduction potential of the 
manganese center, which is very close to the potential of MnSOD itself (12-14, 210, 
211). Other compounds such as polyphenols and flavonoids can have differential effects 
on normal and malignant cells also by targeting anti-oxidant machinery such as 
components of GSH metabolism and NRF2 activation discussed later in this review. 
Mixed oxido-reductase function of compounds like MnTnBuOE are contrary to 
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conventional chemotherapeutics, such as DOX, that can act as oxidizing agents resulting 
from metabolic/bioenergetic alteration or interaction with the cellular redox milieu. With 
this principal in mind, differences in the basal redox environment between normal and 
malignant cells now exposes cancer cells to redox based therapies that offer little harm to 
normal HSPCs (Figure 1.5).   
Redox Based Therapies Targeting the LSC Redox Environment 
The reactive species generated by malignant HSPCs is closely linked to metabolism. 
Thus, as malignant HSPCs or LSC’s undergo clonal expansion at an unchecked rate, in 
comparison to their normal counterparts, the HSPC redox environment has emerged as an 
identifying trait between normal and malignant stem cells (1, 4, 74, 87, 88, 165, 167, 189, 
199, 204). Although most cancer drugs were developed to interfere with DNA synthesis, 
a number of common therapeutic compound classes, already discussed, do in fact induce 
ROS generation. Because the compounds such as DOX, MTX, ETP, cyclophosphamide, 
and cytarabine are all administered to the peril of the normal HSPC, new methods of 
employment must be considered. Transient, low dose regimens and/or combination 
treatments present viable options for safer usage, and several studies within the last 5 
years have begun to explore these options and are reviewed here. 
As previously discussed, the glutathione system has emerged as a key regulator of HSPC 
function and as such may be targeted by redox active compounds for the treatment of 
hematopoietic malignancies. BSO is a potent inhibitor of glutathione synthesis and as 
previously discussed has been used to demonstrate stem cell exhaustion. For this reason, 
clinical utilization of BSO has some potential downfalls. However, Tagde and colleagues 
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have shown the effective combination of melphalan (L-PAM) and BSO in preclinical 
models of multiple myeloma. High GSH levels are indicative of an aggressive multiple 
myeloma (MM) relapse phenotype that may be resistant to L-PAM, depletion of GSH 
with BSO sensitizes 9 MM cell lines and primary MM samples to L-PAM treatment 
(203). This potentiation is blocked by treatment with NAC, which does not change 
cellular GSH concentrations. The combination of BSO and L-PAM results in DNA strand 
breaks, mitochondrial dysfunction, and activation of apoptosis. This combination was 
also successful in depleting GSH and inducing engraftment suppression within 3 human 
MM xenograft models (203).  
The regulation of antioxidant enzyme expression within LSC’s differs vs their normal 
counter parts, but these defense enzymes also differ between types of hematopoietic 
malignancies. For example, CD34+ cells isolated from acute myeloid leukemia (AML) 
patients express low levels of SOD2 and CAT and higher levels of GCLC, GCLM, 
GPX1, and TXN than their normal CD34+ counterparts (163). SOD2 and CAT levels 
vary among other cancers within the myeloid lineage (217, 253). However, elevated 
expression of glutathione metabolism enzymes highlight the importance of glutathione 
regulation within malignant HSPC populations, just as in normal HSPCs. Indeed the 
GSH/GSSG system has successfully been targeted for therapy using several compounds 
that contain α,β-unsaturated-γ-lactone groups or have strong electrophilic character and 
have the potential to react with free thiol groups: parthenolide (PTL) and piperlongumine 
(PLM) (163). Both of these compounds preferentially deplete cellular glutathione levels 
in CD34+ malignant cells compared to normal counterparts. Additionally, PTL and PLM 
treated normal HSPCs demonstrate some degree of GSH/GSSG recovery, whereas the 
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malignant cells do not, offering protection of normal HSPCs and cytotoxic effects in 
malignant HSPCs. The result of this GSH depletion is an increase in cleaved caspase 3 
and cleaved PARP leading to a significant induction of LSC cell death compared to 
normal CD34+ HSPCs. Ultimately PTL was found to actually bind several enzymes 
involved with glutathione synthesis including GCLC and GCLM (163). PTL also 
exhibited a synergistic effect when paired with low doses of cytarabine and idarubicin 
(79).  
PTL and several other natural compounds, including polyphenol and flavonoids, have 
demonstrated potential therapeutic efficacy in chronic myelogenous and lymphocytic 
leukemias. For example, Wu and colleagues evaluated the effects of 27 different 
compounds that include: α-β-unsaturated carbonyls, sulfhydryl reactive metals, 
isothiocyanates, polyphenols, and flavones on NRF2 activation and cytotoxicity in 
PBMCs (peripheral blood mononuclear cells) isolated from normal and CLL patients 
(236). Through the analysis of the NRF2 target HO-1 (heme oxygenase-1) and NRF2 
protein levels, they first found that NRF2 activity was higher in PBMCs from CLL 
patients compared to their normal controls. In all, 6 α-β unsaturated carbonyls, 3 arsenic 
containing sulfhydryl reactive metal, 2 isothiocyanates, 2 flavones, and 5 polyphenol 
compounds were able to activate NRF2 in a FRET β-lactamase based reporter assay in 
HepG2 cells (236). Cytotoxicity evaluation via MTT analysis showed that several α-β-
unsaturated carbonyls, sulfhydryl reactive metals, isothiocyanates, and flavones were 
selectively cytotoxic to primary CLL samples compared to their normal counter parts. In 
the case of PTL and ethacrynic acid (EA), loss of α-β unsaturated carbonyl groups 
diminished NRF2 activation and CLL selective cytotoxicity (236).  
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As discussed previously, Tsai and colleagues were able to utilize the Nrf2-/- mouse model 
to demonstrate a downregulation of homing and chemotaxis of HSPC’s associated with 
the loss of CXCR4 (219). Similarly, an increase in CXCR4 expression resulting from an 
upregulation of CXCL12 results in DOX resistant K562 CML cells (K562/ADM) (232). 
This is characterized by an increase in PI3K activation and NF-kB translocation to the 
nucleus; whereas, CXCR4 siRNA downregulates PI3K/AKT, and IKKα activation 
sensitizing K562/ADM cells to DOX treatment demonstrated by an inhibition of cell 
growth and increase in apoptosis (232). Both in vitro and in vivo, treatment with oroxylin 
A, a monoflavonoid, targets leukemic/ADM cells with low off target toxicity by 
increasing apoptosis via downregulation of CXCR4 expression (232). Taken together, 
these results suggest that compounds such as polyphenols or flavonoids may be able to 
target the malignant cell redox environment through the manipulation of the NRF2 
pathway. As discussed earlier, the flavone baicalein offers protection of splenic and bone 
marrow HSPC from TBI through ERK and NRF2 activation (160). However, in the 
malignant K562 CML cells treatment with both baicalein and baicalin result in an 
increase in NOTCH-1 activation followed by an increase in Hes-1, cyclin D1, Hey-1, and 
Hey-2 mRNA levels (229). This highlights the potential for the redox mediated 
protection of normal tissues with simultaneous targeting of cancer cell populations. 
Additionally, treatment of K562 cells with baicalin and baicalein resulted in an increase 
of cells in G0/G1 phase as well as a decrease of cells entering S-phase and G2/M phase, 
whereas treatment with baicalein only resulted in a decrease of cells in G2/M phase (229). 
This could be due to the metabolic conversion of baicalin to baicalein through the 
cleavage of a glyosidic moiety. Interestingly, both compounds inhibited K562 colony 
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formation in soft agar assays (229). Again, this highlights the ability of redox active 
compounds to selectively target the malignant cellular redox environment, while at the 
same time, offer protection to normal HSPC populations. 
Glutathione homeostasis is also targeted by synergistic combination treatments of 
lymphoid and myeloid cell lines with polyphenol compounds and DOX or ETP (126, 
127, 252). Quercetin, apigenin, emodin, rhein, and cis-stilbene all had synergistic effects 
with DOX and ETP that resulted in cytotoxicity within CCRF-CEM and Jurkat malignant 
lymphoid cell lines. Quercetin and apigenin, however, were the only polyphenols that 
demonstrated synergistic effects with DOX and ETP in THP-1 and KG-1a malignant 
myeloid cell lines. All synergistic effects were closely associated with a decrease of 
cellular GSH, a decrease of ATP production and activation of the apoptosis cascade (126, 
127). Of note, the lymphoid lineage cell lines being most sensitive to this redox based 
combination treatment actually demonstrated the lowest basal levels of GSH, indicating 
that lymphoid cancers may be excellent targets for redox based therapies. Other examples 
of polyphenol induction of LSC cytotoxicity include the use of Nispex, a polyphenol 
mixture that is mainly comprised of quercetin, quercitroside, avicularin and oleandrin. 
This mixture has been proven effective against the AML/HL-60 cell line both in vivo and 
in a xenograft in vivo model (76, 77, 243).  
The HL-60 cell line is one of the earliest malignant promyelocytic leukemia cell lines 
used for the elucidation of chemotherapeutic mechanisms. DOX treatment of HL-60 cells 
results in the activation of caspases 3, 8, and 9 as well as DNA fragmentation (201). The 
development of the HL-60/ADR (DOX resistant) cell line has led to the implementation 
of alternative therapies that include DOX. For example, pre-treatment with a sub-lethal 
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dose of DOX and subsequent combination with TRAIL, a member of the TNF family, 
induces cytotoxicity in the parental and HL-60/ADR cell lines, indicating that DOX 
induced redox signaling even in drug resistant tumor types (105). This occurs through the 
depolarization of the mitochondrial membrane and increased levels of caspase 9 and 
Apaf-1 from the activation of mitochondrial type II apoptosis pathway (105). 
Importantly, HL-60 cells have demonstrated sensitivity to other, more basic redox active 
compounds such as exogenous hydrogen peroxide and the nitroxide compound, tempol 
(150). HL-60 cells demonstrate significant sensitivity to H2O2 induced cell death 
measured by apoptotic markers at concentrations as low as 5 µM, whereas normal bone 
marrow and mononuclear cells isolated from cord blood remain resistant to cell death. 
Primitive populations isolated from normal control were not affected by H2O2 treatment, 
yet CD34+ populations isolated from the HL-60 pool were significantly reduced without 
differentiation at all H2O2 concentrations evaluated. The authors continued to identify 
AKT as a potential mediator of H2O2 induced cell death within progenitor populations of 
HL-60 cells (150). Tempol treatment of HL-60 cells results in a p53 independent 
upregulation of p21, indicating that peroxide generating and nitroxide compounds may be 
promising alternative therapies for chemo-resistant tumor types (72, 150). 
MnSOD has been widely discussed as a tumor suppressor for many years, and just as the 
roles of glutathione homeostasis and catalase activity play important parts of normal and 
malignant HSPC treatment, MnSOD has also been recently demonstrated as a potential 
therapeutic specific to malignant HSCs (152, 255). A phenotypic trait that separates 
HSPCs from LSC’s is the differential expression of various surface markers, such as 
CD33 and CD123 (167). For example, some LSC populations exhibit high levels of 
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CD123 or IL-3R expression whereas normal HSC populations do not (167). This has led 
to a targeted approach for the delivery of MnSOD as a tumor suppressor. Much like the 
liposomal delivery of MnSOD previously discussed in normal HSPCs, Li and colleagues 
utilized CD123 for the targeted delivery of adenoviral particles carrying the MnSOD 
gene. Adenoviral delivery of MnSOD induced dose dependent cytotoxicity in HL-60 and 
KG-1 malignant myeloid cell lines (117). Upon infection, cytotoxicity is accompanied by 
increases in cleaved caspases 7 and 9 as well as increases in cleaved PARP indicating 
mitochondrial activation of apoptosis. Additionally, delivery of MnSOD to xenografted 
HL-60 cells prolonged survival in mice (117). Similar results were seen via treatment of 
murine thymic lymphoma cells. Here, Jaramillo and colleagues found that elevated 
expression of MnSOD increased cellular hydrogen peroxide, sensitizing WEHI7.2 cells 
to glucocorticoid and hydrogen peroxide induced apoptosis. This result was recapitulated 
with the application of MnTE. Although application of MnTE can in some cases produce 
peroxide, sensitization of WEHI7.2 cells may occur through another mechanism, such as 
the oxidation of NF-kB  (93). Additionally, MnTE combination treatment with 
cyclophosphamide inhibited cell growth. No sensitization of WEHI7.2 cells was 
demonstrated in a combination of MnTE and DOX; however, MnTE addition protected 
cardiomyocytes from DOX induced injury (93). These findings have large implications 
for the future of leukemia drug development: delivery of MnSOD to normal HSPC 
populations either by genetic overexpression or treatment with an SOD2 mimetic 
promotes HSPC function while ectopic MnSOD expression or Mn porphyrin (MnP) 
treatment in leukemia cell populations clearly induces cell death (93, 117, 118, 134, 256). 
Furthermore, MnP function within malignant populations may be enhanced by the 
26 
 
presence of other biologically relevant redox active compounds and/or proteins. For 
example, Ferrer-Sueta and colleagues have shown that MnPs may be reduced by enzymes 
such as xanthine oxidase and complex I and II of the mitochondrial electron transport 
chain (59). This reduction shown in submitochondrial particles allows for catalytic redox 
cycling and reduction of peroxynitrite, offering mitochondrial protection against 
peroxynitirite formation and damage (59, 225). Additionally, the combination of MnP’s 
with vitamin C has a promising outlook. Vitamin C itself has demonstrated a protective 
effect against oxidative insult within HL-60 cells (73). However, varying concentrations 
of vitamin C in combination with Mn porphyrins may be effective. Although this 
combination has not been evaluated in HSPC or LSC populations, vitamin C has been 
shown to sensitize pancreatic and breast cancer cell populations through metabolic 
alterations to the cellular redox environment and production of species such as peroxides 
(51, 212, 220). Furthermore, MnP combination with vitamin C has demonstrated 
significant effects on the malignant cell redox environment, primarily through the 
generation of hydrogen peroxide, within prostate and breast cancer, as well as 
glioblastoma cells (55, 212, 250, 257). This strategy is supported by the finding that 
exogenous H2O2 kills primitive LSC’s while leaving normal HSPC populations unharmed 
(150). This indicates that redox active compounds such as MnSOD mimetics, themselves 
or in combination with other redox active drugs, may be able to modulate redox levels 
that support healthy HSPC function leading to the safe eradication of LSC’s from the 
hematopoietic compartment.  
Perhaps one of the most primitive and aggressive of all hematopoietic cancers are 
CML’s. CML patients in blast crisis undergo rapid clonal expansion of progenitor cell 
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compartments and are often resistant to TKI therapies due to altered expression of the 
BCR-Abl fusion gene (41, 83). Redox based therapies, however, offer potential solutions 
to refractory disease. Treatment of the KBM5 and the KBM5-T315I TKI resistant CML 
cell line with ROS inducers such as adaphostin or β-phenylethyl isothiocyanate (PEITC) 
results in complete inhibition of CML cell growth within cell lines and primary samples 
(35, 154, 217, 253). The cytoxicity is based on these ROS inducers ability to modify the 
redox environment of the CML cell that results in the oxidative modification and 
subsequent cleavage of the BCR-ABL protein. The modification of the redox milieu is 
caused by a sharp depletion of cellular glutathione. Decreases in GSH, BCR-ABL 
cleavage and cytotoxic effects are reversed by the pre-treatment of CML cells with NAC. 
Similar effects of BCR-ABL degradation are caused by treatment with BSO. PEITC 
induced cytotoxicity is also observed in primary CML patient samples drawn from 
individuals who display both imatinib sensitivity and resistance (253).  
Similar studies have been conducted in the CD34+ K562 CML cell line. The K562 line is 
a BCR-ABL+ cell line that demonstrates resistance to imatinib. However, K562 cells are 
sensitized to imatinib by co-treatment with simvastatin, a known nitric oxide producer 
(36). The sensitization of K562 cells to this combination treatment is rescued by pre-
treatment with NAC, implying that the production of reactive oxygen species allows for 
successful treatment. This may very well proceed through the depletion of cellular 
glutathione subsequent to the production of peroxynitrite (36). More recently, a 
combination treatment of DOX and polyphenol extract from V. album rescued K562 cells 
from G2/M arrest by expression of cyclins B1 and D1. This resulted in the activation of 
apoptosis and sensitization of K562 cells to DOX treatment (196). Elucidation of redox 
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modifiers that can impact primitive and resistant malignant populations are clearing the 
way for emerging combination treatments, allowing for the use of sub-toxic doses of 
classic chemotherapeutics that, originally, were detrimental to the patient hematopoietic 
compartment. These findings highlight the important ability of redox modifiers to provide 
new solutions for refractory diseases, ultimately improving outcomes for patients with a 
poor prognosis. 
Redox Based Therapies Targeting LSC Metabolism 
Expertly reviewed by Pollyea and Jordan, the LSC redox environment can be specifically 
targeted through differential metabolic profiles between HSPCs and LSC’s (167). 
Potential targets of LSC mitochondrial induced apoptosis are IKK2 (IKB Kinase 2) and 
nuclear factor-κB (NF-kB) (64). Inhibition of NF-kB activation results in mitochondrial 
dysfunction, rupture and cell death. Importantly, NF-kB demonstrates constitutive 
activation in AML and has been used to characterize LSC populations (21, 142). As 
demonstrated in the combination treatment of TRAIL and DOX for refractory AML cells, 
inhibition of NF-kB with small molecules such as JSH-23 or AS602868, also sensitizes 
LSC’s to treatment with TRAIL (56, 64, 208). As mentioned throughout this review, 
targeting glutathione metabolism may also occur in the mitochondria, separating the LSC 
population apart from normal HSPC populations. Recently, however, more exciting 
discoveries have come to light. Several recent studies have identified the isocitrate 
dehydrogenases as redox active targets for cancer therapies. For example, downregulation 
of IDH1 may sensitize cells to hydrogen peroxide production. Conversely, over 
production of the oxidative metabolite 2-hydroxyglutarate sensitizes LSC’s to BCL-2 
downregulation (34, 61, 112, 167). The overproduction of 2-hydroxyglutarate, stemming 
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from mutations in the isocitrate dehydrogenase enzymes may cause epigenetic changes 
that can lead to leukemogenesis (34, 61, 111, 112, 167, 190). Thus, from these studies we 
may learn of redox driven epigenetic events that initialize HSPC transformation in the 
bone marrow niche. Additionally, we have found that the MnTnBuOE porphyrins are 
excellent candidates for the alteration of HSPC and LSC mitochondrial function. 
Treatment of HSPCs with MnTnBuOE results in a decrease of mitochondrial function, an 
increase in antioxidant defense enzyme levels, and an increase in uncoupling protein 
expression eventually offering protection of HSPCs (256). Moreover, as previous 
evidence has suggested, these same changes may have cytotoxic effects in LSC 
populations.  
Targeting the NADPH Oxidase System 
As previously mentioned, normal HSPC irradiation produces a phenotype of HSPC 
exhaustion resulting from DNA damage and the upregulation of cell cycle inhibitor 
proteins leading to HSPC senescence (185, 231). This exhaustion can be protected 
against by treatment with redox active compounds (93, 118, 134, 256). The principal 
mediator of these effects is the ROS produced by the NOX enzymes, implicating NOX 
enzymes as potential redox based therapeutic target for leukemia’s (82, 94, 129, 166, 
197). Aggressive sub-populations of AML can be identified by internal tandem 
duplication of the FMS-like tyrosine kinase (FLT3-ITD) (176, 197). This population has 
elevated levels of DNA damage and ROS production. However, recent studies, 
particularly those demonstrating that Nox4-/- mice are resistant to a FLT3-ITD mediated 
induction of a myeloproliferative disorder (MPD) phenotype, elucidate NOX as a driving 
factor in the generation or propagation of the LSC (94). These studies further suggest that 
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redox based therapies targeting NOX produced ROS may simultaneously be effective in 
the treatment of LSC’s. Inhibition of the FLT3-ITD signaling via PCK412 treatment 
results in decreased STAT5 signaling and the downregulation of the NOX subunit 
p22phox (235). This and the inhibition of NOX via diphenylene iodonium (DPI) or 
VAS2870 treatment led to a decrease in DNA damage as well as a decrease in hydrogen 
peroxide production in the cytosol and nucleus of AML blast cells. Both culture models 
and primary patient HSCs that demonstrate elevated ROS production by NOX, have 
depleted GSH levels, and diminished antioxidant capabilities (197, 235). These facets 
promote the growth of LSC population over their normal CD34+ counterparts, and this 
growth advantage is also mediated through loss of response to the p38 MAPK signaling 
pathway. Taken together, these results show that just as normal HSPCs undergo 
exhaustion in response to ROS mediated MAPK signaling, malignant LSC populations 
are propagated through NOX induced ROS and loss of their normal p38 MAPK response 
that limits HSPC pools. In addition to NOX inhibitors, this presents another therapeutic 
window for the Mn porphyrins in leukemia therapeutic regimens. The redox-active 
MnTnBuOE and MnTE are able to modulate the cellular redox environment offering 
control over the p38 MAPK, NRF2, and NOX/NQO1 systems that may protect normal 
HSPCs while driving malignant cells to activate cell senescence mechanisms (Figure 
1.5). 
Epigenetic Considerations in LSC Redox Treatments 
Targeting epigenetic characteristics have also become a successful avenue of treatment 
for many hematopoietic disorders including AML, myelodysplastic syndrome (MDS), 
and CML. Several cytogenetic abnormalities have become very prominent across the 
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leukemias, particularly those involving fusion of MLL/ENL and HOXA and NUP98 
genes within AML, BCR-ABL in CML and ALL, and Del5q syndrome in MDS (17, 18, 
26, 36, 102, 113, 184, 190, 196, 207). Aberrant DNA methylation patterns have widely 
been recognized for the characterization of hematopoietic disorders within both the 
myeloid and lymphoid lineage (62, 66, 71, 89, 98). As patient populations grow 
increasingly resistant to therapies, methyl transferase or demethylase inhibitors such as 
the azacytidines and histone deacetylase inhibitors have been developed (186, 190). Even 
still, many patient populations demonstrate resistance to epigenetic therapies. As with 
resistant CML’s, there does seem to be a role for redox active compounds in combination 
treatments that result in sensitization to epigenetic treatments. Recently, inhibition of 
LSD1 demethylase with trans-2-phenylcyclopropylamine (TCP) combined with all-trans-
retinoic acid (ATRA) treatment induced sensitivity in several AML models. This was 
demonstrated by decreased AML engraftment in vivo as well as an increase in the 
expression of differentiation markers such as CD11b (180). This has potential redox 
implications as ATRA has been known to induce ROS mediated embryonic stem cell 
death (30). Additionally, ATRA has been identified as a NRF2 inhibitor and has 
potentiated arsenic trioxide toxicity in human AML cells (224, 230). Combination 
treatment in multiple myeloma with the histone deacetylase inhibitor PXD101 and 
bortezomib induces cell death in primary CD138+ MM cells, but not normal bone marrow 
populations (58). These effects are driven by activation of caspases 3, 8, and 9 with 
coordinate activation of p53 and the p38 MAPK pathway; all of which can be blocked 
with NAC treatment (45, 58, 200, 251). Finally, the methyltransferase inhibitor 3-
deazaneplanocin (DZNep) inhibits the polycomb-repressive complex-2 (PRC2) through 
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upregulation of thioredoxin interacting protein (TXNIP). TXNIP activity then results in 
TXN inhibition and a subsequent increase in oxidative stress that may not be a direct 
result of TXNIP mediated inhibition of TXN itself. This ultimately results in apoptotic 
signaling within AML culture lines as well as primary samples (258). This also identifies 
DZNep as a potential therapy for CML (183, 244). The discovery of TXNIP 
downregulation in AML’s and the identification of PRC2/EZH2 as a target for redox 
based therapies is an exciting advancement (183, 244). Recently the Txnip-/- model has 
identified TXNIP as a crucial regulator of normal LT-HSC function (96, 101).  Txnip -/- 
mice undergo HSPC exhaustion that is characterized by loss of repopulation capacity, 
increased Wnt signaling, decrease in p21 expression, and loss of CXCL12 activity within 
the bone marrow niche (96). Loss of TXNIP, as has been demonstrated in AML’s, results 
in an advanced aging phenotype in which HSC exhaustion and bone marrow failure 
occurs through activation of the p53 and p38 MAPK pathway and induction of cell cycle 
regulators (258). Together, these results demonstrate that the Txnip-/- phenotype closely 
resembles hematopoietic phenotypes characterized by pharmacological induction of 
redox stress or those generated by the selection of ROS high populations. These studies 
highlight the potential redox targeting pathways of normal HSPCs use for maintenance 
within malignant populations. This supports the employment of ROS and redox 
modulation for the successful development of cancer therapies, which are highlighted by 
the protection of normal tissues (Figure 1.5). We have summarized the redox active 
compounds as they have been cited and discussed throughout this review to highlight 
potential areas of therapeutic development that may safely and successfully target 
malignant populations in the future (Table 1.1). 
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Summary 
In the past, the limited, primitive and quiescent state of HSPCs has made it difficult to 
meaningfully evaluate the impacts of redox modification in normal and malignant 
HSPCs. In the last 10 years, we have begun to significantly evaluate and realize the 
important impact that management of the HSPC redox environment has on normal 
hematopoiesis and overall patient outcome. We now know that the HSPC redox 
environment can be manipulated by redox active compounds to protect and improve 
HSPC function while still creating stress conditions that may differentially target 
malignant LSCs. This may be accomplished through combination therapies utilizing low 
dose chemotherapeutics and the implementation of a single redox cycler. To this purpose, 
several crucial pathways, such as FOXO, ATM, NRF2, NOX, NF-kB and p38 MAPKs, 
have emerged as critical HSPC redox regulators.  
Through the years, there has been some debate over the importance of an impact of GSH 
homeostasis in the management of cellular redox environments and the treatment of 
cancers (63). However, within the HSPC compartment, the management of GSH/GSSG 
levels appears to be indispensable. Accurate measurement of cellular GSH and GSSG 
concentrations obviously provides insight to the mechanistic underpinnings of drug 
activity as previously discussed, and new methods of quantitation have emerged allowing 
for GSH measurement in HSPC populations (29, 195). These studies may also aid in the 
identification of therapeutics not previously thought to be redox active. For example, 
lenalidomide (LEN) has been used for the treatment of several hematopoietic diseases 
(130, 184, 207). This compound, an immunomodulatory agent which can aid in the 
restoration of normal hematopoiesis, has demonstrated the redox-mediated activation of 
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AP-1 signaling in multiple myeloma treatment (43). Subsequently, we found that LEN 
can deplete cellular GSH levels in a myelodysplastic syndrome (MDS) model at a level 
and rate similar to DOX (29). This now opens both LEN and MDS to consideration for 
redox based therapies. Additionally, our previous work has demonstrated that modulation 
of MRP1 expression dictates cellular GSH/GSSG concentrations. Most notably, an 
increase in HSPC GSH concentrations are demonstrated in the Mrp1-/- mouse model, in 
which loss of MRP1 results in an increase in HSPC function. These results are 
demonstrated by colony formation assays as well as in vivo serial transplantation 
experiments. Improvements in WT HSPC function, compared to the Mrp1-/- can also be 
recapitulated with the addition of NAC (170). This indicates that ABC transporter 
inhibitors may have a role in the development of leukemia therapies that protect the 
HSPC compartment. Moreover, GSH and GSSG levels appear to be a potential biomarker 
for the redox based therapy candidacy. We have previously found that peripheral 
leukocytes isolated from AML patients contain significantly higher cellular GSH levels, 
resulting in a significant difference in the 2GSH/GSSG ratio between patients and healthy 
donors (29). These elevated GSH levels may be the result of an increase in reactive 
oxygen species produced by malignant cells, relative to healthy cells. Redox active 
therapies must then be able to overcome the increased redox buffer capacity 
demonstrated in malignant cells in order elicit a desired therapeutic effect. Thus, the 
2GSH-GSSG ratio may not only be a marker for disease, but serve as an indicator for 
redox based therapies. Because the cellular redox potential can be calculated based on the 
2GSH/GSSG ratio, we may be able to establish limits of HSPC/LSC redox potentials in 
which we know certain redox based therapies will be efficacious (109, 178). In the future, 
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evaluation of patient cellular redox potentials across diseases (CML, AML, ALL etc.) 
may allow for the prediction of response of disease states to specific redox based 
therapies. 
The focus of these principles should expand to include a better understanding of other 
factors affecting the HSPC redox environment, such as thioredoxin activity and the 
function of TXNIP. Thioredoxin interacting protein has recently been identified as an 
important regulator of the HSPC, where loss results in p38 activation and LT-HSC 
exhaustion (96). If this occurs through NRF2 regulation, TXNIP may emerge as a 
druggable target for the treatment of hematopoietic malignancies. Additionally, 
cytogenetic abnormalities, such as chromosomal rearrangements and deletions, have been 
well documented throughout the hematopoietic diseases, yet major changes in epigenetic 
programming remain unclear. For example, TXNIP studies involving DNA methylation 
status indicate that future efforts must focus on the impact that redox active compounds 
have on the epigenetic regulation of the normal HSPC as well as the malignant LSC. 
Redox evaluation of epigenetic changes in hematopoietic malignancies, such as those 
demonstrated by the isocitrate dehydrogenase enzymes (IDH1/2), may provide valuable 
insight to potential initiating events that drive LSC propagation (34, 61, 108, 111, 190). 
This may provide avenues for new genetic based therapies that utilize the manipulation of 
the LSC redox environment.  
Redox modifiers and redox cycling drugs should be used to elucidate the impact of 
signaling pathways contributing to malignant HSPC expansion. For example, sub-
populations of aggressive hematopoietic malignancies express several isoforms of the 
NOX family, as compared to limited NOX expression in normal HSCs (82, 94, 129). 
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However, in normal HSPCs, increased NOX expression and activity results in 
overproduction of ROS (O2
.-, H2O2) leading to the activation p38 MAPK’s, which results 
in the upregulation of cell cycle regulators. It is unclear if constitutive NOX activity in 
malignant populations leads to the loss of AKT and p38 MAPK regulation over LSC 
expansion or if components within, such as the AP-1 family of transcription factors, 
maybe targeted for redox-regulation by redox active compounds to regain control of 
progenitor compartments undergoing clonal expansion (Figure 1.5). These aspects have 
the potential to improve redox based therapies, providing new directions for safe, 
effective treatments. 
Throughout the work presented here, we focus on the evaluation of the normal and 
malignant redox state and examine response to a novel redox active therapeutic in both 
normal and malignant populations. We present the development of novel methods for the 
evaluation of the HSC redox state. The development and validation of a sensitive and 
robust LC-MS/MS method that utilizes the simultaneous quantitation of reduced and 
oxidized forms of glutathione is described. With this method we are able to show new 
insights into the hematopoietic stem cell redox state within very primitive and small HSC 
populations. Furthermore, we show the versatility of this method in the presence of 
chemotherapeutics and can use these data to evaluate effects on the cellular redox state 
within malignant populations. We further utilize this sensitive methodology to evaluate 
the cellular redox state in the face of a novel redox active therapeutic MnTnBuOE-2-
PyP5+ (MnP). We show that this mimic of manganese superoxide dismutase has similar 
effects on the cellular redox state within normal and malignant hematopoietic populations 
and examine the effects of H2O2 signaling on the cellular redox state as well as 
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transcriptional signal transduction. Through this approach we identify the AP-1 
transcription factor JunB as a potential therapeutic target of MnP and evaluate 
mechanistic control of JunB signaling through redox regulation within a myelodysplastic 
cellular model. We conclude with an evaluation of MnP cytotoxicity within several 
leukemic models and the probable redox factors that contribute to MnP sensitivity. These 
studies result in the elucidation of chemoresistant factors within the cellular redox milieu 
that may modulate MnP toxicity. Notably, the development of the LC-MS/MS 
methodology described in chapter two contribute to the observation that the management 
of glutathione metabolism may significantly contribute to the development of 
chemoresistance within malignant populations, particularly through recycling of oxidized 
glutathione via glutathione reductase. The overall findings described here highlight the 
evaluation of redox states within small hematopoietic populations and how differences 
within cellular redox states may be therapeutically targeted to accomplish the protection 
of normal cellular function while simultaneously targeting malignant cell population for 
safe eradication.  
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Figure 1.1 Hierarchy of the hematopoietic compartment 
 The bone marrow compartment contains a complex and highly regulated hierarchy of cell 
types tasked with maintaining the production and balance of all cells in the blood system. 
Beginning with the most primitive CD34+ LT-HSCs, the ability to self-renew and differentiate 
to downstream phenotypes defines the LT-HSC pool with a decreased capacity for self-renewal 
as differentiation occurs. From the MPP pool, both lymphoid and myeloid cell types develop 
and eventually differentiate into terminal effector cell types seen in the periphery.  
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Figure 1.2 Redox active compounds in the bone marrow niche 
The bone marrow compartment demonstrates oxygen concentrations that range from 1% 
(furthest from the blood supply) to 7% (closest to the blood supply). Low oxygen 
concentrations has been referenced as a factor contributing to the protection and 
quiescence of HSCs. However, upon transformation, LSCs may demonstrate increased 
levels of metabolism and ROS levels, while maintaining a lower antioxidant capacity 
than their downstream progeny. This difference, a product of the oxygen environment, 
may allow for a differential redox insult and targeting of LSCs over normal HSCs driven 
by the introduction of a redox active compound.   
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Figure 1.3 Transformation of the HSC/LSC redox environment 
Normal and malignant HSC’s demonstrate differences in the regulation and management 
of the antioxidant system. Normal HSC’s express higher levels of primary antioxidant 
enzymes SOD and CAT. Malignant HSC’s are subject to elevated levels of ROS 
produced by NOX enzyme and rely on higher cellular concentrations of GSH as well as 
the GSH metabolic system to manage the malignant HSC redox state. 
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Figure 1.4 ROS inducers in the HSC 
A schematic diagram demonstrates the differential effect and graded response of HSC’s to 
various redox active compounds and ROS inducers. Normal hematopoiesis is characterized 
by primitive LT-HSC’s that have the ability to self-renew and differentiate into any other cell 
type. As differentiation occurs, progenitor cell types lose their ability to self-renew. This 
process is accelerated in the presence of potent ROS inducers such as conventional 
chemotherapeutic agents and ionizing radiation. Response to these stimuli results in DNA 
damage response and activation of signaling that results in the upregulation of cellular 
senescence and apoptosis. New evidence now suggests that mild ROS inducers have an 
opposite effect, where generation of a mild ROS milieu results in the activation of antioxidant 
defense pathways leading to an improvement in HSC function. The result is a graded response 
to different levels of ROS stimulant that leads to variations of HSC function and either 
exhaustion or strengthening of the hematopoietic niche. 
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Figure 1.5 Differential redox signaling in the HSC vs LSC 
The pro-survival response of normal HSC’s to mild pro-oxidants has led to the concept 
of differential response to redox cycling compounds between normal and malignant 
HSC’s. Redox active compounds will use the normal levels of ROS produced by 
healthy HSC’s to activate an antioxidant response leading to increased proliferation 
and HSC function. Conversely, LSC’s perpetually produce elevated levels of 
superoxide via aberrant constitutive enzyme activity that can be used by redox active 
compounds to produce second messenger ROS such as hydrogen peroxide. This may 
lead to LSC senescence and death. The theoretical result is the protection of normal 
HSC function with simultaneous cytotoxic, anticancer affects in the LSC population.  
 
 
 
 
 
 
 
The table above summarizes the redox active compounds that have been discussed throughout this review as well as their effects 
within their indicated disease states and normal HSPC populations where applicable. This dual application highlights the potential 
for selective targeting of malignant populations while offering protection to normal HSPCs for many redox active compounds 
discussed and cited within this dissertation. 
4
3 
Table 1.1. Summary of redox active 
therapeutics 
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Chapter Two: Characterizing the Hematopoietic Redox State Through 
Simultaneous Quantitation of Oxidized and Reduced Glutathione via LC-MS/MS: 
An insight into the redox state of hematopoietic stem cells 
 
Introduction:  
Glutathione, γ-L-glutamyl-L-cysteinylglycine, (GSH) is an endogenous tripeptide 
involved in many cellular processes including apoptosis, cellular detoxification, and 
redox signaling (122, 123). Currently, GSH is considered a major cellular reducing agent. 
Intracellular concentrations are high, reported to range from 0.5-10 mM, that aids in 
protection from ROS mediated injury (3, 103, 124). GSH/GSSG homeostasis is tightly 
regulated with depletion or oxidation of the cellular GSH pool leading to the activation of 
anti-oxidant signaling pathways, gene transcription, and GSH synthesis accomplished via 
glutamate-cysteine ligase (GCL) activity. Oxidizing cellular conditions lead to the 
heterodimerization of the GCL subunits, GCLC (GCL catalytic subunit) and GCLM 
(GCL modifier subunit) (10, 247), which results in increased GCL activity. GSH activity 
is subsequently regulated via cycling the cysteinyl thiol (pKa= 8.9) through oxidized and 
reduced states. GSH-mediated cellular detoxification may be accomplished by the direct 
conjugation of GSH xenobiotics and other endogenously produced small molecules via 
glutathione-S-transferase (GST) activity or through the action of glutathione peroxidase 
(GPx), which reduces hydrogen peroxide while GSH is co-oxidized to its disulfide form 
(GSSG) (10, 122, 123, 192). Additionally, GSH may reversibly modulate cellular redox 
signaling via direct glutathionylation of thiol groups within redox sensitive signaling 
proteins. This post-translational modification may also protect thiol groups within redox 
sensitive signaling proteins from permanent modification under oxidizing conditions (46, 
69). Similarly, GSH functions to protect mitochondrial 1-Cys peroxiredoxins from 
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damaging oxidation as the resolving thiol group in thioredoxin-catalyzed peroxidase 
activity in Saccharomyces cerevisiae (162). These functions and aspects of GSH 
homeostasis demonstrate the importance of the GSH/GSSG redox pair in the 
maintenance of the cellular redox state.  
The cellular redox state is commonly characterized by examining the ratio of 
reduced to oxidized species within cellular redox pairs. High intracellular concentrations 
and redox buffer capacity makes this especially true of the GSH/GSSG redox couple (7, 
109, 123, 178). Biochemically, GSH and GSSG may be thought of as components of an 
electrochemical half-cell in which the flux of single electron transfers can be quantified 
by their electrical potential or electromotive force, characterizing the proclivity of the 
GSH/GSSG pair to donate or accept electrons in varying redox states. As a result, 
defining the individual absolute cellular concentrations of GSH and GSSG and applying 
these concentrations, along with measured values for intracellular pH (pHi) and cellular 
volume, to the Nernst equation allows for a more specific analysis of the 2GSH/GSSG 
redox state, the electrical half-cell reduction potential (Ehc) (109, 178). Although living 
biological systems never rest at a state of equilibrium, characterization of the 
2GSH/GSSG reduction potential provides a practical snapshot of cellular redox balance 
(63, 178). Furthermore, evaluation of the 2GSH/GSSG Ehc is a strong indicator of the 
existing redox state of thiol-containing signaling proteins regulated by glutathione.  
The cellular GSH/GSSG ratio is characterized by the equilibrium half-cell 
reaction of glutathione species resulting in the synthesis of two moles of GSH from the 
reduction of one mole of GSSG, thus the glutathione based redox state is dependent on 
cellular GSH concentrations (109, 178). Alternatively, the individual concentrations of 
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GSH and GSSG may be considered when characterizing small dynamic changes in the 
cellular redox state over time. Consequently, an effective evaluation of the glutathione 
based redox state requires a sensitive and accurate method for the quantitation of absolute 
concentrations for both GSH and GSSG. This is particularly important for evaluation of 
the cellular redox state within hematopoietic malignancies manifesting in hematopoietic 
stem-progenitor cells (HSPC’s), a tissue that has inherently limited availability for study 
in vivo. For example, in our experience, purification of murine bone marrow typically 
results in the isolation of approximately 20,000 HSPC’s from a single animal that 
demonstrate the Lin- , Sca-1+, c-kit+ (LSK) phenotype.  
HSPC location and function require cellular quiescence and protection from 
oxidative insult (92, 155, 199). Thus, antioxidant defense is vital to stem cell function. 
This concept is demonstrated by the increase in stem cell function resulting from 
treatment with the anti-oxidant and GSH precursor N-acetylcystiene (NAC) (85). This is 
further demonstrated by the major cellular regulator of transcriptional anti-oxidant 
signaling Nrf2. Nrf2-/- mice are characterized by an increase in HSPC differentiation and 
a decrease in stem cell function, indicating that a loss of cellular antioxidant machinery is 
detrimental to the maintenance of HSPC pools in vivo (219). These observations indicate 
a potential role for glutathione metabolism and maintenance in the regulation of redox 
balance and the resulting effect on differentiation and self-renewal, within normal and 
malignant HSPC’s.  
It is well recognized that regulation of glutathione metabolism is significantly 
affected by the expression and activity of the ABC transporter ABCC1/MRP1 (multi-
drug resistance protein 1)(20, 107, 115, 116). MRP1 has wide tissue expression with the 
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exception of the liver hepatocyte, functioning to efflux GSH, GSSG, and glutathione 
adducted metabolites with a km in the low mM range for GSH and nM to µM range for 
GS-X adducted metabolites (20, 54, 107, 115, 116, 144). While the role of MRP1 in 
metabolism within peripheral and specialized tissues has been well documented, the 
function of MRP1 and its effect on glutathione concentrations as well as the HSPC redox 
state within primitive HSC’s is less understood. This is partially due to the inherently 
limited availability of lineage primitive hematopoietic tissues, which display low 
glutathione concentrations in vivo, and is compounded by the lack of sensitive 
methodologies capable of discerning small dynamic changes in glutathione 
concentrations within these specialized hematopoietic populations. However, the ability 
to accurately quantitate cellular GSH pools within these rare tissues is needed because 
aberrant GSH metabolism may lead to an alteration of the HSPC redox state. These 
changes in HSPC redox balance are closely associated with genetic instability as well as 
proliferation, differentiation, and mobility within the HSPC populations in which 
hematopoietic disorders are thought to initiate and reside (90-92, 209). As such, 
examining the GSH/GSSG based HSPC redox state may provide insight to the role of 
MRP1 and the glutathione redox pair in the onset and progression of hematopoietic 
neoplasms. Additionally, many cancer therapies, including radiation and 
chemotherapeutics, such as the anthracyclines, are known to exert a portion of their 
tumor killing effect through the production of ROS, which may be remediated by 
adduction of GSH and efflux via MRP1, further altering the malignant cell redox state. 
Together, these facets indicate that accurate measurement of GSH/GSSG will aid 
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interpretation of MRP1 function in HSPC’s and how alterations in the cellular redox state 
may affect hematopoietic disease onset, progression, and treatment.  
 Many current methodologies utilized for GSH and GSSG quantitation are based 
on free thiol conjugation followed by the observation of a fluorescent product, enzymatic 
reduction of glutathione disulfide pools, and the chemical derivation of parent glutathione 
molecules allowing for chromatographic separation (22, 27, 151, 169, 175). These 
methodologies require complicated chemical reactions, which may not reach completion, 
and large amounts of sample tissue. Moreover, some methodologies may only accurately 
measure total glutathione content and are not effective or ideal for accurately quantitating 
GSH/GSSG in small cell populations in vivo, such as HSPC’s. However, emerging 
methods that combine high performance liquid chromatography with single or tandem 
mass spectrometry (LC-MS, LC-MS/MS) with and without post column sample 
modification have quantitated GSH/GSSG in physiological fluids (32, 195). While these 
methods demonstrate the potential power of LC-MS/MS analysis, they do so within an 
effectively unlimited sample population. Here we describe the development and 
validation of a simple tissue extraction combined with a robust and sensitive LC-MS/MS 
method, demonstrating high throughput potential, for the direct and simultaneous 
quantitation of oxidized and reduced forms of glutathione in small HSPC populations. 
The application of this methodology is demonstrated in cell culture systems as well as 
mouse bone marrow, including purified Lin-, c-kit+, Sca-1+ (LSK) populations. 
Validation procedures performed were based on the recommended guidelines for LC-
MS/MS based analysis of small molecules in industry as set forth by the United States 
Food and Drug Administration (2). As a method and model control, we examine cell 
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populations demonstrating differential expression of MRP1 resulting in the 
characterization of MRP1 functional effect on glutathione concentrations within primitive 
HSPC populations in vivo. This control allows us to evaluate whether this LC-MS/MS 
method can detect fine variations in glutathione concentrations with both in vitro and in 
vivo systems. We have found that the over expression of MRP1 in MCF7 cells results in 
decreased intracellular GSH/GSSG concentrations, while loss of Mrp1 expression in 
Mrp1-/- HSPC’s resulted in the cellular accumulation of GSH and GSSG. These results 
indicate that MRP1 expression may have a direct impact on the cellular redox state of the 
HSPC population. Additional evaluation of the utility for this methodology is completed 
through the quantitation of glutathione within cultured MDSL cells treated with 
chemotherapeutics (doxorubicin and lenalidomide) that have been previously used for the 
treatment of hematopoietic disorders such as acute myeloid leukemia (AML) or 
myelodysplastic syndromes (MDS). Furthermore, we characterize glutathione 
concentrations in normal human bone marrow as well as mononuclear cells isolated from 
patients afflicted with acute myeloid leukemia.  We found that acute myeloid leukemic 
cells derived from human bone marrow demonstrate elevated levels of GSH, indicating a 
potential mechanism by which leukemic stem cells balance elevated levels of oxidative 
stress produced during proliferation. 
Materials and Methods 
HPLC Grade LC-MS/MS Materials 
γ-L-Glutamyl-L-Cysteinyl-Glycine (GSH), γ-glutamyl-L-cyteinyl-glycine 
disulfide (GSSG), ethylenediaminetetraacetic acid (EDTA), were purchased from Sigma-
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Aldrich (St. Louis, MO). Trichloroacetic acid was purchased from J. T. Baker (Center 
Valley, PA). Chromatographic columns were purchased from Phenomenex (Torrance, 
CA). HPLC grade solvents were purchased from Fisher Scientific (Pittsburgh, PA). 
Formic acid and ammonium formate were purchased from Acros Organic (Pittsburgh, 
PA). 
Cell Culture 
  MDSL cells, a gift from Dr. Tohyama of Kawasaki Medical School, Okayama, 
Japan, were cultured in complete MDSL media containing: IMDM media (ATCC; 
Manassas, VA) supplemented with 20% FBS (GE Healthcare; Pittsburgh, PA), 1% 
penicillin/streptomycin (Life Technologies; Grand Island, NY), and 15 ng/mL 
recombinant human IL-3 (Peprotech; Rocky Hill, NJ). MDSL cells were cultured at both 
5% and 21% O2, 5% CO2, at 37º C. MCF7 cells were cultured in DMEM media (Life 
Technologies; Grand Island, NY) supplemented with 10% FBS and 1% 
penicillin/streptomycin in 5% CO2 at 37ºC. MRP1 overexpressing MCF7 (MRP1-10, a 
gift from Dr. Charles Morrow, National Institute of Health, Bethesda, Washington DC) 
cells were cultured in DMEM media supplemented with 10% FBS and 1% 
penicillin/streptomycin, 1.0 mg/mL G418, in 5% CO2 at 37ºC. 
LC-MS/MS Methodology 
Mass spectrometric analysis was performed on a TSQ Vantage triple quadrupole 
mass spectrometer (Thermo Fisher Scientific, Waltham MA) coupled with an ion max 
electrospray ionization source containing a HESI II probe operated in positive ion mode. 
The GSH/GSSG MS/MS method development was accomplished by direct infusion of a 
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GSH/GSSG standard (10 µg/mL) into the mass spectrometer at a flow rate of 5 µL/min. 
Single reaction monitoring (SRM) was used to simultaneously analyze samples for GSH 
and GSSG. The SRM’s for GSH (m/z 308.0 → m/z 84.0 + 161.9) and GSSG (m/z 613.1 
→ m/z 231.1 + 354.9) were completed with collision energies and S-lens voltages 
optimized for each individual transition. Other MS/MS method settings follow: Q1 and 
Q3 resolution at 0.7 FWHM, scan width at 0.1 amu, scan rate at 0.1 seconds, and 
collision gas pressure at 1.0 mTorr. Tune parameters were as follows: spray voltage at 
2700 V, vaporizer temperature at 200° C, capillary temperature at 250° C, sheath and 
auxiliary gas pressures at 35 and 10 arbitrary units, respectively. Liquid chromatography 
was performed on a Shimadzu LC system containing a CBM-2A controller, a SIL-2A 
auto sampler, and two LC-20 AD pumps (Canby, OR). Liquid chromatographic 
separation of 10 µL sample injections were achieved on a Phenomenex Luna PFP(2) 
analytical column (100 mm x 2.0 mm, 3 µm) and completed under isocratic conditions, 
99% mobile phase A (H2O, 0.75mM ammonium formate, 0.01% formic acid), 1% 
solvent B (methanol) at 250 µL/minute over an 11 minute total run time.  
Calibration Standards and Quality Control’s 
 Stock solutions of GSH and GSSG were prepared at 1 mg/mL by dissolving 1.0 
mg of pure powder stock in 1.0 mL of 2% TCA (1mM EDTA). One hundred µL aliquots 
were then frozen at -80° C for no more than 7 days. Working stock solutions were created 
by 1:10 serial dilutions of the 1.0 mg/mL stock solutions in 2% TCA (1mM EDTA). A 
working GSH/GSSG stock solution was mixed at 10 µg/mL and subsequently used to 
dilute working standard concentrations of 500.0, 250.0, 100.0, 50.0, 25.0, 10.0, 7.5, 5.0, 
2.5, 1.0, 0.5 ng/mL for simultaneous GSH/GSSG standardization of the LC-MS/MS 
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system. QC solutions of 5.0, 25.0, and 250.0 ng/mL (five injections at each 
concentration) were also diluted from the 10 µg/mL working GSH/GSSG stock solution. 
Standard curves and QC’s were prepared and run on each day of analysis. Data 
acquisition and sample peak integration analysis was completed with Xcalibur software, 
version 2.1 (Thermo Fisher). Standard, QC, and sample concentrations were calculated 
with sample peak areas and linear equations (form y = mx + b) generated by external 
standard curves for both GSH and GSSG.  
Sample Extraction Methodology 
Samples, prepared as described below, were pelleted in a 5 mL round bottom tube 
by centrifugation in a swinging bucket rotor at 1300 rpm for five minutes. Supernatants 
were carefully discarded by vacuum aspiration. Cells were then re-suspended in 75 µL of 
extraction buffer (2% TCA; 1.0 mM EDTA) and incubated on ice for 15 minutes after 
which samples were vortexed for 45 seconds and incubated on ice for a further 15 
minutes. Sample pH was adjusted to 2.0 by mixing 50 µL of sample lysate with 50 µL of 
Mobile phase A (HPLC grade H2O, 0.75 mM ammonium formate, 0.01% formic acid, 
pH=3.0) and cellular debris was subsequently pelleted by centrifugation at 4,000 x g for 
10 minutes. Supernatants were collected for LC-MS/MS analysis.  
Method Validation 
The linear range of detection for both GSH and GSSG was determined and 
validated by the analysis of the standard curve and QC samples generated as described 
above (n=3). A linear regression was used to determine the correlation coefficient (r2 
value) after plotting the analyte peak area over the standard concentration. The inter-day 
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slope precision was expressed as the percent of the coefficient of variance (%𝐶𝑉 = (
𝜎
𝜇
) ∗
100). Analyte stability at various temperatures was determined by repeat analysis at the 
lowest QC concentration (n=5) and is presented as percent of the concentration originally 
measured. Inter and intra-day precision was determined by repeat standard and QC 
evaluation at three different concentrations within the determined linear range in 
replicates of five (n=3). Again, precision is presented as %CV. The lower limit of 
detection (LLOD) was determined by the lowest peak height that generated a signal to 
noise ratio (S/N) greater than or equal to three (S/N ≥ 3) for both GSH and GSSG. The 
lower limit of quantitation (LLOQ) for both analyte species was identified as the 
minimum analyte concentration required to generate a signal to noise ratio greater than or 
equal to five (S/N ≥ 5) as determined by standard addition analysis described below.   
Because GSH and GSSG are produced endogenously, the cellular lysates 
produced during sample extraction serve as the biological matrix. Thus, precision, 
accuracy and percent recovery were evaluated by standard addition of known analyte 
concentrations to whole cell lysates which were extracted at 30,000 cells per aliquot of 
lysate. Mouse whole bone marrow was used for cross validation. Here, individual lysates 
of 30,000 cells/sample were spiked with known amounts of standard GSH/GSSG 
solution. To accomplish standard addition of MDSL cell lysates, 1.2 million MDSL cells 
were lysed in 3.0 mL of extraction buffer (30,000 cells/ 75 µL of extraction buffer). 
Then, 75 µL of lysate was added to 75 µL of blank extraction buffer or extraction buffer 
containing four times the target analyte (GSH/GSSG) concentration and samples were 
then incubated on ice for 30 minutes. After incubation, sample pH was adjusted to 2.0 by 
mixing 50 µL of sample containing the blank lysate, +/- standard with 50 µL of mobile 
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phase A. Samples were then spun down at 4,000 x g for 10 minutes and analyzed via LC-
MS/MS. Standard addition of mouse whole bone marrow was completed by preparing 
individual aliquots of 30,000 cells to which 75 µL of either blank extraction buffer or 
extraction buffer containing two times the target analyte concentration of GSH/GSSG 
was added. Samples were then incubated on ice for 15 minutes after which the samples 
were vortexed for 45 seconds each, followed by another 15 minute incubation period on 
ice. Cellular debris was then pelleted by centrifugation at 4,000 x g, and the supernatants 
were collected for LC-MS/MS analysis. Standard addition for both cell types was 
completed at 4 concentrations; 0.0, 5.0, 50.0, 250.0 ng/mL for GSH and 0.0, 1.0, 5.0, 
50.0 ng/mL for GSSG. Each standard addition concentration was evaluated in replicates 
of n=5. Target analyte concentrations were evaluated by subtracting the basal 
GSH/GSSG concentrations obtained by LC-MS/MS analysis of the blank samples from 
the GSH/GSSG concentrations calculated from the standard addition samples. Precision 
values at each standard addition concentration are expressed as % CV, described above. 
Accuracy values are expressed as % bias, which is taken as the percent deviation of the 
determined experimental concentration from the proposed theoretical concentration 
((
(𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑉𝑎𝑙𝑢𝑒−𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑉𝑎𝑙𝑢𝑒
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑉𝑎𝑙𝑢𝑒
) ∗ 100). The percent recovery values were 
determined as the [(
(𝑇𝑜𝑡𝑎𝑙 𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛−𝑇ℎ𝑒 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝐵𝑙𝑎𝑛𝑘 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
) ∗
100]. 
GSH/GSSG Analysis of Cultured Cells 
MRP1 protein expression in MCF7 WT and MRP1 overexpressing MCF7 
(MRP1-10) cells was evaluated by flow cytometry analysis after incubation with a FITC 
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conjugated antibody targeted to the first nucleotide binding domain (amino acids 617-
932) of human ABCC1/MRP1. MCF7 and MRP1-overexpressing MCF7 (MRP1-10) 
cells were plated at 100,000 cells per well in 12 well plates and were subsequently 
incubated in 5% CO2 at 37° C for 24 hours to allow for cellular attachment. Cells were 
then mechanically harvested, counted by hemocytometer and 50,000 cells per sample 
were aliquoted into 500 µL of PBS (pH=7.0 for LC-MS/MS analysis of GSH/GSSG as 
described above. Similarly, prior to analysis, MDSL cells were plated at 200,000 
cells/mL in a 24 well plate and were then incubated in 5% or 21% O2, 5% CO2, at 37° C 
for 24 hours. Cells were then counted by hemocytometer and samples were diluted in 500 
µL of PBS (pH=7.0) prior to LC-MS/MS analysis of GSH/GSSG. Total GSH and GSSG 
concentrations (ng/mL) were converted to ng/sample by multiplying by total sample 
volume, sample concentrations were then divided by the total number of cells extracted, 
normalized to 20,000 cells per sample and reported as [GSH] and [GSSG] in ng/20,000 
cells. 
LSK Purification by FACS Analysis 
 Femurs and tibias were harvested from wild type (WT) and Mrp1 knock out (KO) 
mice of the C57BL/6 background. Subsequently, bone marrow was aspirated with FACS 
buffer (PBS, 2% HI-FBS pH=7.4) using a 2 mL syringe and a 27.5 gauge needle (BD 
biosciences, San Jose, CA). Whole bone marrow was then pelleted by centrifugation at 
1600 rpm for 3 minutes and the supernatant was discarded. Cells were then washed twice 
with FACS buffer. Whole bone marrow was then re-suspended in red blood cell lysis 
buffer (150 mM NH4Cl, 10mM NaHCO3, 1 mM EDTA), filtered through a 5 mL (12 x 
75 mm) polystyrene round-bottom tube with a cell strainer cap (BD Falcon, San Diego, 
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CA) and incubated on ice for 5 minutes. Cells were then spun down at 1600 rpm for 3 
minutes and the supernatant was discarded. Cells were then washed twice with FACS 
buffer and re-suspended in 100 µL of FACS buffer. After re-suspension cells were 
incubated with 2 µL (1:50 ratio) of conjugated antibody corresponding to cell surface 
markers used for sorting Lin- , Sca-1+, c-kit+ hematopoietic stem cells (LSKs) on ice for 
60 minutes. The antibodies used for sorting LSK’s were as follows: Sca-1, Ly-6A/E-PE-
Cy7; c-kit, CD-117-PerCP-Cy5.5; Lineage, Cd45R-APC-Cy7, Cd3e-APC-Cy7, Ter199-
APC-Cy7, Cd19-APC-Cy7, and Cd11b-APC-Cy7 (all antibodies listed are raised in rat, 
anti-mouse and were purchased at 0.2 mg/mL from BD Pharmigen, San Diego, CA). 
Subsequent to incubation, cells were washed and then re-suspended in 500 µL of FACS 
buffer for fluorescence assisted cell sorting of LSKs at the University of Kentucky flow 
cytometry facility. There, Lin- , Sca-1+, c-kit+ HSC/MPP’s from both WT and Mrp1 KO 
mice were sorted such that LSKs from two mice were pooled as  n = 1 for GSH/GSSG 
analysis. Thus, six mice of each genotype were sorted as three separate experimental 
preparations (n=3). LSKs were then taken directly to the University of Kentucky 
Proteomics Core for analysis of absolute GSH/GSSG concentrations via LC-MS/MS.  
Cell Viability 
 MDSL cells were plated at a density of 200,000 cells/mL in complete MDSL cell 
medium containing either vehicle or drug (10 µM Lenalidomide, Cayman Chemical, Ann 
Arbor MI; or 25 nM Doxorubicin, Pfizer, New York, NY) in a 24 well plate and were 
incubated for 48 hours. Cells were then transferred to 5 mL round bottom tubes and 
washed twice with warm HBSS (pH=7.4)( Gibco-Thermo Fischer, Waltham, MA). Cells 
were then re-suspended in MTT solution (0.5 mg/mL 3-(4, 5-dimethylthiazolyl-2)-2,5-
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diphenyltetrazolium bromide, Sigma Aldridge St. Louis, MO; in RPMI media with no 
phenol red Gibco-Thermo Fischer, Waltham, MA), aliquoted into a 96 well plate, and 
incubated at 37ºC for 4 hours. Equal volumes of lysis buffer (50/50, v/v, 
isopropanol/DMSO) were added to each well followed by a 30 minute incubation at 
37ºC. Samples were then evaluated for absorbance at 560 and 690 nm using a Molecular 
Devices SpectraMax Plus 384 plate reader with SoftMax Pro software. 
Therapeutic Drug Treatments  
 MDSL cells were plated at a density of 200,000 cells/mL in complete MDSL cell 
medium containing either vehicle or drug (10 µM lenalidomide, Cayman Chemical, Ann 
Arbor MI; or 25 nM doxorubicin, Pfizer, New York, NY) in a 24 well plate and were 
incubated for 6 hours. Samples were then transferred to 5 mL round bottom centrifuge 
tubes, extracted, and GSH/GSSG concentrations were analyzed via LC-MS/MS as 
previously described.  
Patient Sample Collection and Analysis 
Peripheral blood and bone marrow samples were obtained by Dr. Diana Howard, 
from the Markey Cancer Center after individuals gave informed consent for tissue 
donation. White blood cells were isolated by Ficoll gradient centrifugation as follows; 
patient tissue (21 mL of blood or bone marrow) was diluted to 50 mL with phosphate 
buffered saline (Sigma Aldridge). Samples were then layered over 13 mL of Histopaque 
(Sigma Aldridge) and centrifuged at 1400 rpm for 45 minutes. The white blood cell layer 
was then carefully removed, diluted in freezing media (IMDM, 10% FBS, 1% 
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penicillin/streptomycin, 10% DMSO) and stored in liquid nitrogen (-180° C) until the 
time of LC-MS/MS analysis, as described above.  
Statistics 
 Statistical analysis for method validation was completed as described by the 
USFDA guidelines for LC-MS/MS bioanalytical method validation. Lower limits of 
detection were taken as the analyte derived signal that produced a peak with a signal to 
noise ratio 3 times greater than the background matrix. The lower limit of quantitation is 
defined as the analyte concentration required to generate a signal to noise ratio greater 
than or equal to 5 times the signal to noise ratio of the background matrix. For specific 
guidelines see the method validation section above. Inter and Intra-day precision are 
presented as a percent of the coefficient of variance (%CV). Calculations are based on 
replicate measurements (n=5) at three different QC concentrations, three separate times 
(n=3). Accuracy is presented as a percent bias of experimentally observed concentrations 
compared to the theoretical concentrations measured in replicate analysis (n=5) for 3 
different concentrations, 3 separate times (n=3). Standard curves are presented with a 
95% confidence interval based on 3 separate measurements (n=3). GSH and GSSG are 
statistically compared separately between control and genetic or treatment groups. P-
values between control and treatment groups are calculated via t-test (n=3).  Unless 
otherwise stated, error is presented as the standard error of the mean derived from at least 
three experimental repeats containing a minimum of triplicate measurements. 
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Results 
LC-MS/MS Method Development and Validation 
Past liquid chromatographic separation of glutathione has been accomplished with 
common reverse phase C18 columns. However, we have found that GSH retention on 
these analytical columns is minimal. Squellerio et al., (195) described utilization of the 
Luna PFP-2 reverse phase column (Phenomenex) for the efficient retention of both 
glutathione species in the LC-MS/MS analysis of GSH and GSSG from human whole 
blood samples. In agreement with their findings, we found the Luna PFP-2 column to be 
the optimal tool for chromatographic retention and separation of the oxidized and reduced 
glutathione species. While previous mass spectrometric based methodologies for the 
analysis of GSH/GSSG in physiological fluids have been characterized, these methods 
are applied to the analysis of samples for which there effectively is a nearly unlimited 
supply (32, 195). To our knowledge, none have examined the limits of sensitivity and 
potential for analysis of fine changes in GSH/GSSG concentrations within rare and 
limited tissue populations, such as hematopoietic stem cells in vivo.  
To determine the quantitative limit for tissue sample analysis of GSH/GSSG 
concentrations in vitro and demonstrate the effectiveness and sensitivity of these 
analytical parameters in vivo, we developed a modified LC-MS/MS method for direct and 
simultaneous GSH/GSSG quantitation. The product ion spectra obtained were evaluated 
by the comparison to product ion spectra acquired from the direct infusion of pure 
GSH/GSSG standard (Figure 2.1A). The chromatographic resolution of GSH and GSSG 
was confirmed by the collection and evaluation of full product ion spectra resulting from 
the analysis of GSH and GSSG from a biological sample (Figure 2.1B). Upon completion 
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of the LC-MS/MS SRM method development, the average retention times for GSH and 
GSSG elution from the Luna-PFP2 reverse phase column, calculated from QC analysis 
were 2.69 +/- 0.02 and 4.37 +/- 0.03 minutes respectively (mean +/- SD, n=15).  A 
typical extracted ion chromatogram obtained from LC-MS/MS analysis of a 25 ng/mL 
standard is shown in Figure 2.2. Figure 2.3 demonstrates the typical results obtained from 
GSH/GSSG standard curve analysis. Although separate external GSH and GSSG 
standard curves are generated, standard data acquisition occurred simultaneously.  
The method validation summary (Table 2.1) includes all parameters for LC-
MS/MS method validation as recommended by the USFDA(2). The lower limit of 
detection for both GSH and GSSG was 0.5 ng/mL as demonstrated by chromatographic 
peaks that have a signal to noise ratio greater than 3. Precision, lower limits of 
quantitation (LLOQ) as determined by accuracy measurements at various QC 
concentrations, and analyte recovery were all determined by standard addition analysis. 
The lower limits of analyte quantitation were 5.0 ng/mL for GSH and 1.0 ng/mL for 
GSSG.  
The USFDA recommends that accuracy values, which are defined as the 
closeness of a concentration value obtained by the analytical method to the actual 
concentration value, and precision values, defined as the closeness of individual measures 
of an analyte when the procedure is applied to multiple aliquots of a single homogenous 
solution of biological matrix, must be evaluated at three different concentrations within 
the analyte’s linear range and must have five repeat evaluations at each concentration. 
These analyte evaluations must have mean coefficient of variance values within 15% at 
medium and high concentrations within the analyte’s linear range, and 20% at the LLOQ 
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(2). Table 2.1 summarizes the results of this LC-MS/MS method validation. Analyte 
stability was evaluated at the lowest QC concentration (5 ng/mL) for storage at 3 
different temperatures. Our results agree with those previously reported, demonstrating 
good GSH/GSSG stability within 15%, at +4° C and -80° C. However, GSH stability, at 
the LLOQ, was slightly diminished (-23%) at room temperature after a period of 24 
hours. Slope and inter/intra-day precision values had coefficient of variance values less 
than 10% (Table 2.1). A full method validation was completed in MDSL cell lysates in 
which the accuracy values were all within 20% at the LLOQ (GSH, 17.4%; GSSG, -
1.6%) and medium to high concentrations demonstrated CV values of less than 5% 
(Table 2.1). Precision %CV values were less than 15% at all concentrations for both GSH 
and GSSG. Analyte recovery values, evaluated by standard addition, were all within 10% 
of full analyte recovery for both GSH and GSSG. Finally, a method cross validation by 
evaluation of accuracy and precision via standard addition was completed in the mouse 
whole bone marrow biological matrix. Accuracy and precision coefficient of variance 
values were determined to be within 15% at all concentrations for both GSH and GSSG. 
Biological Method Evaluation 
 To test the potential for this method to evaluate varying glutathione levels in 
biological systems, we utilized a system with altered expression of Multidrug Resistance-
associated Protein 1 (ABCC1/MRP1). We first measured GSH/GSSG levels in MCF7 
wild type cells, known to not express MRP1, and compared these results to the 
GSH/GSSG measurement within MCF7 cells overexpressing MRP1 (MRP1-10 cells). 
Differential MRP1 expression between the two MCF7 cell lines was confirmed by flow 
cytometric analysis of FITC conjugated antibody directed to the first nucleotide binding 
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domain of human MRP1 (Figure 2.4). Figure 2.5A shows that overexpression of MRP1 
resulted in a significant decrease in cellular GSH and GSSG concentrations, -0.65 ng/20k 
cells for GSH, and -0.13 ng/20k cells for GSSG (p=0.001). Figure 2.5B shows that MRP1 
overexpression in MCF7 cells (MRP1-10 cells) results in a significant increase in the 
GSH/GSSG ratio, +5.3 (p=0.01). 
 This method was then used to evaluate GSH/GSSG concentrations in the absence 
of MRP1 in vivo. Both WT and Mrp1-/- C57BL/6 mice were obtained and their 
hematopoietic stem cells (Lin-, sca-1+, c-kit+; LSK’s) were isolated via fluorescence 
assisted cell sorting (Figure 2.6). The typical yield for this isolation was approximately 
20,000 cells from a single animal. The results demonstrated that the LSK cells from 
Mrp1-/- mice had a significant increase in cellular GSH concentrations (+4.6 ng/20k cells, 
p=0.01). Although differences in the GSSG concentration were observed in LSK cells 
isolated from Mrp1-/- and WT mice, these changes were not judged to be statistically 
significant (Figure 2.7). These results demonstrate the robustness and sensitivity of our 
LC-MS/MS methodology and its ability to detect fine differences in GSH/GSSG 
concentrations within very limited tissue populations.  
Both the over expression and knock out of Mrp1 expression within various cell 
types resulted in an increase of the GSH/GSSG ratio. This indicates that the evaluation of 
the individual cellular concentrations of GSH and GSSG and not only their concentration 
but also their ratio is useful for an accurate interpretation of the GSH/GSSG based 
cellular redox state.  
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To further validate the utility of the methodology, MDSL cells were evaluated for 
GSH and GSSG concentrations after treatment in vitro with two clinically relevant 
chemotherapeutic agents, doxorubicin (Adriamycin) and lenalidomide (Revlimid). 
Traditionally, high risk MDS patients presenting with blast crisis have been treated with 
high dose cytarabine plus an additional course of an anthracycline such as doxorubicin. 
Because doxorubicin is a known ROS inducer, due to its metabolic formation of an 
intermediate semi-quinone structure, we compare the treatment effect and generation of 
ROS via doxorubicin to that of lenalidomide. Lenalidomide is known to act as an anti-
inflammatory agent as well as a stimulant of lymphocytes and erythropoiesis (44, 130, 
145, 179). However, there is evidence that suggests lenalidomide can, itself, induce 
oxidative stress. This is observed in the use of lenalidomide for the treatment of a 
multiple myeloma model in which the combination of lenalidomide and the spin trap, 
ROS scavenger, phenyl-N-t-butylnitrone (PBN) effectively modulates the transcriptional 
activation of AP-1 family transcription factors (43). Recently, lenalidomide has been 
proven to be effective in the treatment of MDS mouse models and has a significant 
cytotoxic effect in vitro, at 10 μM (173). Doxorubicin (25 nM) and Lenalidomide (10 
μM) treatment of MDSL cells results in 21% (p=0.04) and 18% (p=0.02) decreases in 
MDSL cell viability, respectively (Figure 2.8). Similar treatment effects are also 
demonstrated on cellular GSH and GSSG concentrations in vitro. A 6 hour treatment of 
MDSL cells with Doxorubicin resulted in a 19% depletion of GSH (-5.72 ng/20k cells, 
p=0.03) and a 15% (-0.019 ng/20k cells, p=0.03) depletion of GSSG compared to vehicle 
control (Figure 2.9). Similarly, 6 hour in vitro treatment of MDSL cells with 
Lenalidomide resulted in a 10% (-2.09 ng/20k cells, p=0.01) depletion of GSH and a 15% 
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(-0.013 ng/20k cells, p=0.02) depletion of GSSG, compared to vehicle controls (Figure 
2.9). Because the decreases in GSH and GSSG upon treatment were very fine, there was 
no significant difference in the GSH/GSSG ratio’s between treatment and control groups. 
This again points to the importance of individual species concentration determination 
rather than the examination of the ratio between the reduced and oxidized forms of 
glutathione alone. Furthermore, the elucidation of such minor, yet significant, changes in 
analyte concentration demonstrates the sensitivity and robust nature of this methodology.  
Patient Sample Evaluation 
 Because cellular GSH/GSSG concentrations could play a significant role in 
disease onset and progression, changes in cellular GSH/GSSG concentrations and the 
cellular redox state may potentially serve as a biological marker for disease onset or 
severity. As such, we set out to evaluate GSH/GSSG concentrations in Ficoll purified 
white blood cell populations from patient samples donated by healthy individuals or those 
who had a confirmed case of a hematopoietic malignancy. We measured GSH/GSSG 
concentrations in 5 samples collected from healthy bone marrow (NBM), and 6 samples 
from patients diagnosed with acute myeloid leukemia (AML). Figure 2.10 shows a 
significantly higher GSH levels in AML compared to the NBM samples (+ 18.57 ng/mL), 
resulting in an increased GSH/GSSG ratio (+2.87). This elevated GSH/GSSG redox state 
may compensate for the elevated oxidative stress levels that malignant cells utilize for 
proliferation and disease progression.  
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Discussion 
 Recently, several mass spectrometric based methodologies have directly 
evaluated oxidized and reduced glutathione extracted from physiological fluids. These 
methods measure GSH/GSSG concentrations without the need for the enzymatic 
reduction or chemical derivation of glutathione or glutathione disulfide prior to endpoint 
detection (22, 32, 151, 195). While effective, previous methods have been applied only to 
large sample pools in which the limits of sample volume and method sensitivity are not 
an issue. Following the USFDA Guidance for Industry on Bioanalytical LC-MS/MS 
Method Validation, we have developed and described the validation of a sensitive and 
robust LC-MS/MS method for the simultaneous and direct quantitation of the oxidized 
and reduced forms of glutathione. We apply this methodology to the quantitation of GSH 
and GSSG at the cellular level, and we use this method to determine the lower limit of 
tissue volume required for accurate cellular GSH/GSSG quantitation. We have 
demonstrated the quantitation of cellular GSH/GSSG within the murine stem cell 
populations and the potential for GSH/GSSG analysis within HSCs derived from an 
individual animal. Our analyses enable the determination of the physiologically relevant, 
functional effect of MRP1 expression on the glutathione based redox state within 
primitive HSC populations. Here, loss of MRP1 expression results in an increase in 
cellular glutathione concentrations, creating a more reducing intracellular environment. 
This result indicates that MRP1 may play an important role in regulating redox balance 
within HSC’s and thus influencing the ability or proclivity for HSCs to self-renew or 
differentiate into downstream functional populations. Additionally, the ability to detect 
clinically relevant treatment induced variations in glutathione concentrations within 
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hematopoietic tissues, as demonstrated by the treatment of MDSL cells with doxorubicin 
and lenalidomide, show that this methodology may be capable of providing valuable 
insight to treatment toxicity as well as efficacy as it pertains to the modulation of the 
cellular redox state in vivo. 
Because of the critical role of glutathione in cellular redox balance and signaling, 
we believe that the tissue extraction and LC-MS/MS method described here will become 
an important tool for examining how the cellular redox state may affect or be affected by 
the development and treatment of hematopoietic neoplasms.  Based on the data obtained 
from human samples, we speculate that elevated redox stress within malignant 
hematopoietic cells may be compensated with elevated levels of GSH and that the altered 
redox state may support disease onset as well as drive disease progression(100). The 
results suggest that there is a potential for the future use of cellular GSH/GSSG 
concentrations as a bio-marker for hematopoietic cancer; however, a much larger patient 
cohort must be evaluated. 
GSH concentrations in the nucleus account for 10-15% of total cellular GSH, and 
1-2% of this total cellular GSH pool residing in the nucleus may be resistant to depletion 
by chemical agents such as L-buthionine-[S,R]-sulfoximine (BSO) (23, 52, 53, 97, 206). 
Thus, characterization of nuclear GSH concentration and function can indicate GSH 
utility in nuclear protection from oxidant insult, resulting in the faithful conservation of 
DNA replication and improved DNA repair capabilities. Similarly, mitochondrial GSH 
may account for up to 30% of cellular GSH (123, 125, 133, 192). This mitochondrial 
pool of GSH protects other sulfhydryl containing proteins and may partially regulate the 
function of ATPases, transporters, and dehydrogenases by buffering the cellular redox 
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status in the face of oxidative challenge (192). Due to its sensitivity, our method may be 
utilized for the evaluation of GSH/GSSG concentrations within separate subcellular 
fractions, such as nuclear extracts and purified mitochondrial preparations. Future efforts 
to characterize subcellular GSH pools within rare tissue populations may be 
accomplished by adopting this LC-MS/MS methodology into an ultra-high pressure 
liquid chromatographic (UHPLC) system. The features of UHPLC-MS/MS analysis 
result in tighter peak widths and greater peak heights resulting in improved overall 
analyte sensitivity and higher throughput potential. Utilization and further development 
of the methods we describe here can have an important impact on redox biology research 
as it pertains to the development of hematopoietic malignancies in limited and rare tissue 
populations as well as the impact of redox balance on subcellular function.
 
 
Figure 2.1GSH/GSSG MS/MS spectra  
A.) Both GSH (top) and GSSG (bottom) were infused in line with a 50% solvent A (H2O,  0.1% formic acid), 50% solvent B (acetonitrile, 
0.1% formic acid) LC flow (200 µ/in) at a rate of 5 µL/min and at concentrations of 10µg/mL. The resulting product ion spectra were obtained 
from GSH and GSSG parent ions. B.) The chromatograms and spectra above resulted from the injection of a cellular extract isolated from 
mouse LSK cells. The spectra below each chromatogram display the product ion spectrum for the highlighted chromatographic peak above. 
Comparison of these spectra with the infusion spectra (A) shown above confirms the presence of GSH and GSSG. 
6
8
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Figure 2.2 Chromatographic separation of GSH and GSSG 
The chromatograph above demonstrates the simultaneous separation of reduced (GSH, 
middle) and oxidized (GSSG, bottom) forms of glutathione. This injection sample 
consisted of 10 µl of a 25 ng/mL QC sample (0.25 ng on column) routinely run during 
instrument standardization.  
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Figure 2.3 External linear range of GSH and GSSG standards 
The linear plots above are examples of typical standard curves for both GSH and GSSG. 
Although separate curves are generated, GSH and GSSG standardization of the LC-MS/MS 
system takes place simultaneously. 1 mg/mL standards for GSH and GSSG are prepared in 1% 
TCA (1.0 mM EDTA, 50% solvent A). These standards are then mixed at 10 µg/mL each and 
are subsequently diluted down in a stepwise fashion with 1%TCA (1.0 mM EDTA, 50% 
solvent A) to create the working solutions of standard and QC concentrations displayed in the 
linear range above. Fresh standards and QC’s are prepared the day sample analysis takes 
place. Data are presented with a 95% confidence interval, n=3. 
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 Table 2.1 GSH/GSSG LC-MS/MS method validation summary 
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Table 2.1 GSH/GSSG LC-MS/MS method validation summary 
The table above summarizes the results of the LC-MS/MS method validation for the 
simultaneous analysis of reduced and oxidized forms of glutathione. The Lower Limit of 
Detection and Quantitation were taken as the concentrations which exhibit a signal greater 
than or equal to that of three (LLOD) and five (LLOQ) times the intensity of a blank matrix 
injection respectively. All standards and QC’s had an injection volume of 10 uL and were 
analyzed using the LC-MS/MS method previously summarized. Inter-day standard and slope 
analysis was completed over 3 days with a linear range of 0-500 ng/mL. QC’s levels 
evaluated were at 5, 25, and 250 ng/mL over 3 days for inter-day precision analysis. Intra-day 
precision analysis was completed with an n=5 for each concentration on the same day. 
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Figure 2.4 MRP1 expression in MCF7 cells 
MRP1 expression evaluated with a FITC conjugated antibody in MCF7 WT (red), and 
MCF7 cells overexpressing MRP1 (MRP1-10, blue and orange). 
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Figure 2.5 MRP1 expression effects on cellular GSH and GSSG concentrations 
A) Mean GSH/GSSG concentrations were evaluated in MCF7 WT and MCF7 cells 
overexpressing MRP1 (MRP1-10). Significant differences in GSH concentration between 
MCF7 (1.46 ng/20k cells) and MRP1-10 cells (0.81 ng/20k cells) were determined (p=0.001). 
Additionally, significant differences in GSSG concentration between MCF7 (0.19 ng/20k 
cells) and MRP1-10 cells (0.06 ng/20k cells) were determined (p=0.001). B) Average 
GSH/GSSG ratios between MCF7 WT (7.5) and MRP1-10 (12.8) cells were found to be 
significantly different (p=0.01). GSH and GSSG were statistically compared separately 
between the two genetic groups via t-test (n=3), *p< 0.01. Error is expressed as standard error 
of the mean. 
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Figure 2.6 FACS isolation of LSK populations 
Fluorescence Assisted Cell Sorting (FACS) purification of Lin
-
, Sca-1
+
, c-kit
+
 (LSK) 
hematopoietic stem cells (HSC’s). Bone marrow from C57BL6 wild type (WT, Bottom) and 
Mrp1 knock out (KO, Top) mice used for GSH/GSSG analysis. This analysis routinely resulted 
in the purification of approximately 20,000 cells per mouse. 
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Figure 2.7 Cellular glutathione concentrations in LSK populations 
The concentrations of GSH, GSSG and their cellular ratio determined in WT and Mrp1 KO 
mouse LSK cells purified as described earlier. The graph depicts the differences in analyte 
concentrations between genotypes. A significant difference in mean GSH concentration is 
demonstrated between the Mrp1 KO (5.64 ng/20k cells) and WT (1.04 ng/20k cells) animals 
(p=0.01). A difference in the GSSG concentration between genotypes was found (KO, 1.07 
ng/20k cells vs WT, 0.17 ng/20k cells) but this difference was not statistically significant. 
Similarly, no significant statistical difference in GSH/GSSG ratios was determined (KO, 8.56 vs 
WT, 6.16). GSH and GSSG were statistically compared separately between the two genetic 
groups via t-test (n=3), *p< 0.05. Error is expressed as standard deviation. 
77 
 
 
  
Figure 2.8 Chemotherapeutic toxicity in MDSL cells 
MDSL cell viability was evaluated via MTT assay after 48 hour treatment with 25 nM 
doxorubicin and 10 µM lenalidomide in vitro. Both treatments resulted in a significant 
decrease of cell survival, 21% for doxorubicin (p=0.04) and 18% for lenalidomide (p=0.02) . 
Results are expressed as percent cell survival normalized to their individual vehicle control 
and as such are statistically evaluated as separate groups using the t-test (n=3), *p<0.05. Error 
is expressed as standard error of the mean. 
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Figure 2.9 Chemotherapeutic depletion of GSH and GSSG 
MDSL cell GSH (A) and GSSG (B) concentrations were analyzed after 6 hour drug 
treatment in vitro. Both Doxorubicin (25 nM) and Lenalidomide (10 μM) caused 
significant depletion of GSH and GSSG (Dox GSH -5.72 ng/ 20k cells, p=0.03; Dox 
GSSG -0.019 ng/20k cells, p=0.03; Len GSH -2.09 ng/20k cells, p=0.02; Len GSSG -
0.013 ng/20k cells p=0.01). Each analyte species and treatment group was statistically 
evaluated separately in comparison to their own unique vehicle controls using a t-test 
(n=3), *p<0.05. Error is presented as standard error of the mean. 
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Figure 2.10 Glutathione concentrations in patient samples 
Mean GSH, GSSG concentrations and their cellular concentration ratio 
analyzed within lymphocytes purified from the peripheral blood and bone 
marrow of AML and normal healthy donors. LC-MS/MS analysis revealed a 
significant increase in GSH concentrations within the AML (28.15 ng/mL, 
n=6) vs NBM (9.58 ng/mL, n=5) sample populations (p=0.03), resulting in a 
significant increase in the GSH/GSSG ratio, 3.94 in AML vs 1.16 in NBM 
patients (n=5, p=0.04). No statistically significant difference was determined 
in GSSG concentrations between patient groups (AML, 8.77 ng/mL vs 
NBM, 7.73 ng/mL). Analyte groups were evaluated separately via t-test, 
error is expressed as standard deviation. 
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Chapter Three: Mechanistic Insights to a Redox Based Therapy for Myelodysplastic 
Syndromes 
Introduction 
The myelodysplastic syndromes (MDS) are a heterogeneous group of 
myeloproliferative disorders (MPD) that clinically present with multiple cytopenia’s 
within the myeloid lineage, a diverse set of cytogenetic abnormalities, and elevated blast 
cell counts within the periphery. There are several accepted methods for evaluating MDS 
and patient prognosis that include the World Health Organization (WHO), French 
American British (FAB), and International Prognostic Scoring System (IPSS) systems. 
Generally, these methods are used to evaluate the combinations of patient pathologies 
resulting in a prognostic score acting as an outcome predictor that aids in treatment plan 
identification. Patients who demonstrate few cytopenia’s with only one cytogenetic 
abnormality such as a deletion on chromosome 11, and low blast cell counts of less than 
2% in the periphery are given a very good risk score and a good prognostic outlook. 
These individuals may receive treatment that supports normal hematopoiesis such as 
erythropoietin, stem cell factors, and granulocyte-macrophage stimulating factors, to 
combat potential risk of progressing cytopenia’s and development of anemia. Higher risk 
patients who display several chromosomal rearrangements and deletions as well as 5% to 
greater than 10% blast cell content within the periphery may receive first line therapies 
that include hypomethylating agents and lenalidomide (138-141). However, nearly 50% 
of patients show poor response to therapy. Those patients who are of high risk may 
receive treatment for acute/chronic myeloid leukemias in blast crisis that includes 
cytarabine alone or in combination with an anthracycline, with the only total curative 
measure being an allogenic bone marrow transplant. However, advanced age and severity 
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of disease within most patients limits treatment aggression and contributes to poor overall 
survival rates. 
While MDS is a relatively rare bone marrow disorder, approximately 30% of 
patients progress to onset of acute myeloid leukemia (AML). This offers potential insight 
into latent hematopoietic failure that is a prelude to prolific expansion of myeloid 
compartments after complete malignant transformation. Thus, MDS offers a platform for 
the identification of not only factors that contribute to bone marrow failure and cancer 
development, but also elucidation of specific molecular targets that may be developed for 
therapeutic applications. Because MDS is a relatively rare disorder, reliable model 
systems that incorporate several facets of developed MDS are particularly useful (174). 
Wunderlich and colleagues have described the development of NOD/SCID based 
mice that contains a complete IL-2 receptor γ-chain (IL-2R) knock out (NSG mice) and a 
separate model that express human forms of interleukin 3 (IL-3), stem cell factor (SCF), 
and granulocyte-macrophage colony stimulating factor (GM-CSF) (NSS mice) (237). The 
cross between the two mice results in the generation of the NSGS mouse model, a 
NOD/SCID mouse that contains an IL-2R knock out and also expresses hIL-3, hSCF, and 
hGM-CSF that allows for enhanced engraftment capabilities through decreased immuno-
rejection and cytokine supported clonal expansion. The development of the NSG and 
NSGS mice have allowed for improved engraftment of pre-leukemic and fully 
transformed malignant cells in vivo (237). More recently, Rhyasen, Starczynowski and 
colleagues have utilized these mouse models for the successful engraftment of a patient 
derived clonal MDS cell line (MDSL) for the study of lenalidomide and an interleukin 
receptor associated kinase-1 (IRAK1) inhibitor efficacy (173, 174). The engraftment of 
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the MDSL cell line has proven to be a useful tool for modeling the latent MDS 
transforming to an aggressive form of MDS with significant engraftments within the bone 
marrow and spleen. This MDSL cell line derived from a patient in the non-leukemic 
phase of a myelodysplastic syndrome has been previously characterized as a 
stem/progenitor phenotype that expresses both CD34 and CD38 and has low potential for 
differentiation making it ideal for the identification of druggable mechanistic targets 
within a non-leukemic clone (130, 174). 
As previously discussed, increased resistance to hypomethylating agents, 
malignant transformation, and aggressive treatment options for patients of advanced 
disease and age, all point to the need for more effective therapeutics in areas that include 
not only the suppression of malignant expansion, but the restoration of normal 
hematopoiesis within the bone marrow niche. Recently, JunB has been identified as a key 
factor for controlling the expansion of myeloid progenitor compartments. JunB deficient 
models demonstrate the development of a myeloproliferative disorder in vivo, which 
closely resembles myelodysplastic syndromes (156-158, 177). Within 3-6 months, JunB 
deficient mice demonstrate granulocytic progenitor and blast cell expansion within bone 
marrow and spleen followed by penetration of peripheral organs that is transferrable to 1° 
and 2° naive recipients (156-158, 177). This MPD progresses through a defect in LT-
HSC differentiation through loss of response to Notch, TGF-β, and Wnt signaling as well 
as INK4a cell cycle regulators (156-158, 177). These seminal studies present JunB as a 
potentially druggable target that may aid in the return of normal hematopoiesis within 
myeloproliferative disorders. Because the AP-1 family of transcription factors are known 
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to be regulated by alterations to their intermolecular redox status, we examine the 
potential application of redox therapeutic approach to JunB activation. 
We have recently discovered that the manganese porphyrin MnTnBuOE-2-PyP5+ 
(MnP) successfully aids normal hematopoiesis through short-term and multipotent 
progenitor cell populations, made evident most notably through naive tertiary transplant 
recipients receiving donor derived bone marrow treated with MnP in vivo (256). This 
occurs through a redox mechanism that relies on the MnP metabolism of superoxide and 
the production of hydrogen peroxide. Because MnP has been extensively characterized 
and has demonstrated anti-tumor activity in a variety of malignant cancer models (15, 93, 
210, 211), we evaluate MnP in vitro as a potential MDS therapy and utilize the MDSL 
cell line to identify redox modification of the AP-1 family transcription factor JunB, and 
present JunB as a viable drug target for MnP treatment of MDS.  
Materials and Methods 
Cell Culture and Treatments 
MDSL cells were cultured in complete MDSL media: IMDM medium containing 
1x penicillin/streptomycin and 20% FBS. MDSL cell culture media was supplemented 
with 15 ng/mL human IL-3 (Peprotech; Rocky Hill, NJ). All cultures were kept in a 
humid environment at 37° C supplemented with 5% CO2. MnP was synthesized and 
characterized by Dr. Ines Batinic-Haberle and her colleagues at Duke University School 
of Medicine; Durham, NC. Where indicated, MnP treatment alone was accomplished by 
supplementing culture medium with drug at indicated concentrations and durations. 
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Where indicated, cells were treated with PEG-Catalase (Sigma Aldrich, St. Louis, MO) at 
a concentration of approximately 80 Units/cell for 12-16 hours overnight. 
Cell Viability 
Cell viability was determined by two different assays. First, viability was 
determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) assay. Cells were plated at a density of 100,000-200,000 cells/mL and were 
incubated with indicated drug treatments for 48 hours. At the time of analysis, samples 
were collected and transferred to 5 mL round bottom polystyrene tubes (Corning; 
Harrodsburg, KY), pelleted via centrifugation at 1300 rpm for 5 minutes and 
subsequently washed twice with sterile PBS. Samples were then resuspended in DMEM 
media containing no phenol-red supplemented with 0.5 mg/mL MTT reagent. Cells were 
re-plated in a 96 well plate at 30,000 cells/well and incubated at 37° C (5% CO2) for 3.5 
hours. Cells were then lysed with 1:1 (v/v) DMSO and isopropanol and incubated for 25 
minutes in the dark. Absorbance was then measured at 560 and 690 nm. Additionally, 
cell viability was determined by flow cytometry. Normal human bone marrow cells 
purchased from All Cells were rapidly thawed and washed 3 times with IMDM media 
after which cell viability was accounted for via trypan blue staining. Cells were then 
plated out and treated with MnP at indicated concentrations over night for 18 hours. Cells 
were then collected and washed twice with PBS. Samples were then incubated with 
fluorochrome conjugated antibodies to CD34 and CD38 in FACS buffer (PBS, 2% FBS) 
for 1 hour in the dark. Samples were washed in FACS buffer and resuspended in 500 μL 
FACS buffer containing 5 μL of 5 mg/mL propidium iodide. Samples were then 
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evaluated for viability by exclusion of propidium iodide via flow cytometry with an LSR 
II (BD Biosciences; Franklin Lakes, NJ). 
Glutathione Quantitation, Cellular Volume, Intracellular pH and Reduction 
Potential Calculation 
We have previously summarized the development, validation, and implementation 
of simultaneous GSH and GSSG quantitation via LC-MS/MS. Briefly, treated samples 
and controls were transferred, at 30,000 cells per sample, to 5 mL round bottom 
polystyrene centrifuge tubes and were subsequently pelleted at 1300 rpm for 5 minutes. 
Supernatants were vacuum aspirated and cells were subsequently lysed in an ice cold 2% 
TCA solution containing 1 mM EDTA, vortexed for 30 seconds and incubated on ice for 
15 min. Samples were then vortexed a second time and were further incubated on ice for 
15 minutes. Cellular debris was then pelleted at 4,000 x g for 10 minutes and sample pH 
was adjusted to 2.0 prior to LC-MS/MS analysis. Samples concentrations were calculated 
based on external standard curve analysis with the linear form 𝑦 = 𝑚𝑥 + 𝑏. Sample 
concentrations in ng/mL were converted to moles of analyte using the molar mass for 
glutathione and glutathione disulfide. This conversion was then used to calculate the 
molar analyte concentrations per cell after cellular volume determination.  
Cellular diameter was determined via the Coulter principal and electrical 
impedance. This was accomplished with a Scepter cell counter (Millipore Sigma; 
Burlington, MA). Samples were collected, washed twice with PBS and analyzed with a 
40 μm sensor. Average cellular diameters were then used in the equation for the volume 
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of sphere, 𝑉 =
4
3
𝜋𝑟3, to calculate cellular volume. This value was used to divide analyte 
concentrations (moles) resulting in cellular molar analyte concentrations.  
Intracellular pH was evaluated with BCECF (2’,7’-bis-(2-carboxyethyl)-5-(and-
6)-carboxyfluorescein) (Invitrogen) fluorescence. High potassium Ringer’s solutions 
(142.3 mM KCl, 1.0 mM MGCl2, 1.5 mM CaCl2, 10 mM NaCl, 20 mM HEPES) were 
prepared for standard curve analysis at various pH values (6.21, 6.85, 7.17, 7.77). Cell 
samples evaluated as standards were washed and resuspended in Ringer’s solution of the 
designated pH and were subsequently treated with nigericin (3 μM) for H+/K+ 
equilibration for 30 minutes at room temperature. 1.0 x 106 cells were treated with either 
vehicle or MnP. Samples were then washed and both standards and samples were treated 
with 3 μg/mL BCECF in PBS for 1 hour at room temperature. Samples and standards 
were then washed and fluorescence was measure at excitation 440/490, emission 530.  
Molar concentrations were then used to calculate the glutathione-based half-cell 
reduction potential at 25°C, pH 7.0 as summarized by Schaffer and Buettner (178). 
 𝐸ℎ𝑐 = −240 − (
59.1
2
) log (
[𝐺𝑆𝐻]2 
[𝐺𝑆𝑆𝐺]
) 
Measurement of Intracellular Hydrogen Peroxide 
Measurement of intracellular hydrogen peroxide has been previously described by 
Wagner and Buettner (227). Briefly, samples and controls were plated in 6 well plates, 
treated with 20 mM 3-aminotriazol (Sigma Aldrich; St. Louis, MO) and subsequently 
harvested at 0, 5, 15, 30, 45, and 60 minutes. Cells were washed and subsequently lysed 
in 250 uL of 50 mM phosphate buffer pH 7.0 via sonication; 500 uL of 30 mM H2O2 in 
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phosphate buffer was added to 1.0 mL of sample and the loss of absorbance at 240 nm 
was observed at 15 second intervals for 2 minutes. The natural log of the result from each 
time point is plotted against time (in seconds) and the slope is taken as the first order rate 
constant for the inactivation of catalase in the presence of 3-AT (kinactivation). Steady state 
hydrogen peroxide concentrations are then calculated from the equation: 
[H2O2]ss=kinactivation/k1 
Where k1= 1.7 x 10
7 M-1s-1, which is the rate constant for compound I formation in the 
presence of hydrogen peroxide. 
Transcription Factor ELISA Array 
Transcription ELISA kit was obtained from Signosis (Santa Clara, CA) and all 
procedures were conducted according to the instructions provide with the assay kit. 
Briefly, 10 x 106 cells were plated in 6 well plates overnight and were subsequently 
treated with vehicle or MnP for 1 hour. Samples were collected and nuclear extracts were 
obtained according to the kit manual procedures. Extracts were then mixed with free 
transcription factor probes in binding buffer at room temperature for 30 minutes. 
Unbound probe was then removed by centrifugation through an isolation column 
equilibrated with binding buffer. Bound probes were then eluted and denatured in DNA 
free ddH2O at 98°C for 5 minutes. Eluted probe was then hybridized to the hybridization 
plate overnight at 42°C. Plate wells were then blocked in blocking buffer at room 
temperature for 5 minutes followed by incubation with the diluted HRP-conjugates and 
incubated at room temperature for 45 minutes. Wells were then washed 3 times and 
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substrate was added to each well followed by a 1 minute incubation. Luminescence was 
then evaluated with a 1 second integration time. 
Western Blotting 
Western blots were prepared as follows. 3.0 x 105 cells were lysed in standard ice 
cold RIPA buffer with protease and phosphatase inhibitors for 30 minutes on ice. Cellular 
debris was removed by centrifugation at 10,000 rpm for 10 minutes. Equal amounts of 
protein were then diluted with 2x Laemmli sample buffer (Bio-Rad Laboratories; 
Hercules, CA) and boiled at 95°C for 5 minutes. Samples were then resolved in a 10% 
SDS-PAGE gel at 160 V for 90 minutes. Proteins were transferred to a nitrocellulose 
membrane at 100 V for 60 minutes. Membranes were blocked with 5% milk in TBST 
(pH=7.4) for 60 minutes before the indicated primary antibodies were administered and 
incubated for 16 hours, overnight at 4°C. Membranes were washed with TBST and 
incubated with HRP-conjugated secondary antibodies for 60 minutes prior to detection 
with ECL reagent (GE Healthcare; Pittsburgh, PA) on x-ray film (Denville Scientific; 
Holliston, MA). Protein quantitation was determined using image J software (NIH; 
Bethesda, MD) by band intensity normalization to β-actin controls (n=3). 
DNA Binding Assay 
Cells (100 x 106 ) were plated overnight in 25 cm dishes and were treated with 
vehicle or MnP for 1 hour. Samples were collected and washed with PBS. Samples were 
then resuspended in buffer A (60 mM KCl, 15 mM NaCl, 0.5 mM spermidine, 15 mM 
HEPES, 0.05% NP-40, containing protease and phosphatase inhibitors and containing 0.3 
M sucrose). Samples were then mechanically lysed with a Teflon pestle homogenizer and 
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centrifuged for 10 minutes at 3,500 rpm, 4°C. Samples were then resuspended in buffer A 
containing 0.3 M sucrose (0.2% NP-40); 10 mL of 0.9M sucrose was added and samples 
were centrifuged for 10 minutes at 3,500 rpm, 4°C. Nuclear pellets were collected and 
resuspended in DNA binding buffer (20 mM TrisHCl pH 7.4, 185 mM NaCl, 5% 
glycerol, 0.1% Triton X-100, 0.1% NP-40, containing protease and phosphatase 
inhibitors). Samples were then briefly sonicated and biotinylated double stranded oligo 
nucleotide containing tandem repeats of the consensus AP-1 DNA binding motif (5’-
Biotin-TGAG/CTCA-3’) was added (5 μg) with 3000-fold molar excess of salmon sperm 
DNA. Samples were then incubated on ice for 1 hour and were subsequently centrifuged 
at 3,500 rpm for 10 minutes at 4°C. Nuclear extracts containing the protein DNA 
complex were then incubated with 40 μL of streptavidin linked sepharose beads (50% 
slurry) for overnight at 4°C. Beads were then pelleted by centrifugation at 14,000 rpm for 
15 minutes at 4°C and were subsequently washed twice with DNA binding buffer to 
remove non-specific protein binding. Beads were then removed and bound protein was  
collected by heating to 95°C in 2x loading buffer followed by centrifugation at 14,000 
rpm for 15 minutes at 4°C. JunB protein was then evaluated by western blotting as 
previously described.  
Immunoprecipitation 
MDSL cells (10 x 106 ) were plated in a 6 well plate and incubated in complete 
growth medium overnight. Samples were then treated with vehicle (ddH2O) or 20 μM 
MnP for 1hr. Cells were collected and washed twice with PBS. Cells were lysed in ice 
cold RIPA buffer and were subsequently incubated on ice for 30 min. Cellular debris was 
then pelleted by centrifugation at 10,000 rpm for 10 min at 4°C. Lysates were collected 
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and protein concentration was measured via BCA assay; 20 ug of primary antibody was 
added to 500 ug of lysate and samples were then incubated with rotation at 4°C 
overnight. Protein A/G conjugated agarose beads (20 μL, 50% slurry) was added and 
samples were incubated with rotation at 4°C overnight. Beads were then pelleted by 
centrifugation at 14,000 rpm for 15 minutes at 4°C. Samples were then washed with 
RIPA buffer and beads were pelleted for a second wash. Loading buffer (40 μL of 2x) 
was then added and samples were heated at 95°C for 5 minutes. Samples were then 
collected by centrifugation and were subsequently analyzed by Western blotting. 
Biotin-1,3-cyclopentadione (BP-1) pulldowns were accomplished by treating 10 x 
106 cells with vehicle or MnP for 1hr, washing cells in 1 mL of PBS, and resuspending 
cells in PBS containing 5 mM BP-1 for 15 minutes at room temperature. Excess BP-1 
was then removed by centrifugation and washing twice with PBS. Pellets were then 
incubated for 30 minutes at room temperature to allow for the chemical modification of 
sulfenic acid with BP-1. After 30 minutes samples were lysed in PBS, that was 
previously rendered free of oxygen via nitrogen gas infusion, and containing 1% Triton 
X-100, 0.5% NP-40, 2 mM iodoacetamide, ˃200 Units of bovine catalase for 30 minutes 
at room temperature in the dark. Lysates were collected and 10 μg of protein was 
aliquoted for loading controls. Streptavidin linked sepharose beads (50 μL,50% slurry) 
was added to each sample followed by incubation overnight at 4°C with rotation after 
which time samples were collected and analyzed by Western blot as described above.  
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Lentiviral Production and Transduction 
Separate lentiviral plasmids containing shRNA’s directed towards JunB and Ref-1 
were obtained from GeneCopeia (Rockville, MD) and lentiviral particles were produced 
in 293Ta cells according to the manufactures protocol. Briefly, 1.3 x 106 293Ta cells 
were plated in a 10 cm dish. 48 hours later the cells were transfected with the lentiviral 
plasmid and a packaging plasmid mix complexed with a transfection reagent. Fresh 
media was placed in the dish 14 hours after transfection. Lentivirus was harvested 48 
hours after transfection. Lentivirus was then purified by ultra-centrifugation at 25,000 
rpm for 90 minutes. Supernatants were discarded into 20% bleach solutions and lentiviral 
particles were resuspended in fresh IMDM media by aspiration (100x) followed by a 2 
hour incubation period and another round of aspiration. Lentivirus was sterile filtered and 
diluted in complete MDSL growth media. MDSL cells were then plated out in a 24 well 
plate at 30,000 cells per well in 500 μL of lentiviral supernatant followed by a 48 hour 
incubation period. Viral supernatants were then discarded to a 20% bleach solution and 
cells were plated in fresh growth media for another 48 hours. Samples were collected and 
sorted by flow cytometry based on protein tag expression. Sorted cells were then plated 
in growth media containing 0.2 μg/mL puromycin for antibiotic selection and 
establishment of stable knock down cell lines.  
Statistics 
 Statistical analysis for immunoblotting comparing band intensity between 
treatment and control groups for at least three replicate experiments was completed via t-
test, significance is reported at p<0.05. Cell viability containing multiple drug 
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concentrations of a single test group were completed by one-way ANOVA and those with 
multiple test groups were completed by two-way ANOVA, with post hoc evaluation. 
Transcriptional activity was completed with n=3 and error for fold change from vehicle 
control is reported as standard deviation. Unless otherwise stated, all other error is 
presented as the standard error of the mean derived from at least three experimental 
replicates containing multiple measurements for each group. 
Results 
Our initial studies utilizing MnP have been accomplished in the WT C57BL6 
background mouse model. This work has paved the way for a new understanding of how 
redox stress levels differentially effect the hematopoietic stem cell and it’s environment 
(256). Because we have found that MnP imparts a significant improvement to normal 
HSC function, we have evaluated its potential as an anti-cancer agent. We first compare 
MnP effects on malignant MDSL and normal mononuclear cells isolated from the bone 
marrow of healthy individuals. We found a significant dose dependent increase in MnP 
mediated cytotoxicity within the MDSL cell line (IC50= 31.3 μM, Figure 3.1A), with no 
induced differentiation from the stem/progenitor (CD34+ CD38+) (Figure 3.1B). MnP 
treatment of normal mononuclear blood cells (MNBC’s) results in improved overall 
frequency of viable CD34+ cells with a highly significant increase in CD34+ CD38+ cells 
(Figure 3.1 C-E). These results agree with our previous findings, which demonstrate MnP 
mediated enrichment of hematopoietic function through the upregulation of antioxidant 
capacity. This further supports the overall safety of MnP toxicity and founds future 
efforts in characterization of MnP effect on whole niche dynamics. Furthermore, this 
presents the possibility that MnP may differentially target intracellular redox states of cell 
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populations that coexist, such as normal and malignant populations occupying the bone 
marrow during malignant transformation and progression of disease. 
 To further investigate the effect of MnP on the intracellular malignant redox 
environment, we evaluated the overall 2GSH/GSSG ratio via glutathione quantitation and 
calculation of the half-cell reduction potential. Although there is some debate over the 
relevance of GSH in some aspects of redox biology, HSC dependence on GSH/GSSG 
metabolism is well documented. Because MnP is a redox active porphyrin that cycles the 
complexed manganese through single electron transfer and the metabolism of 2GSH to 
GSSG involves a two-electron process in which hydrogen ions are potentially liberated, 
we not only have to accurately account for absolute analyte concentrations, but also for 
any alterations to the intracellular pH after MnP treatment. Intracellular pH was measured 
via BCECF fluorescence and was calculated using external standards equilibrated with 
high potassium solutions via an antiporter at various pH values. We found that MnP 
treatment does not significantly alter physiological intracellular pH (Table 3.1). We then 
used the diameter of the cell measured by electrical impedance (Table 3.2) to calculate 
the cellular volume, which was combined with dual analyte quantitation via LC-MS/MS 
to calculate the intracellular molar concentrations of both reduced and oxidized 
glutathione after MnP treatment (Table 3.3). MnP in fact does reduce cellular glutathione 
levels, resulting in a decrease in the cellular reduction potential of approximately +10 mV 
at both 4 and 16 hours of treatment (Figure 3.2). This indicates that MnP induces the 
same mild ROS elevation in malignant cells, as it does in normal populations. Further 
investigation of catalase inhibition revealed that MnP treatment causes an increase in 
steady state hydrogen peroxide levels from 14 pM to approximately 20 pM. While no 
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significant increase in catalase activity occurs, this fine alteration of the true intracellular 
redox environment towards more oxidizing conditions is the key facet of MnP that allows 
for differential targeting of malignant cells over their normal counter parts. Pretreatment 
of the MDSL cells with PEG-catalase prior to MnP completely protects the MDLS cells 
from MnP induced cytotoxicity (Figure 3.3). Thus, while this H2O2 production leads to 
cellular protection and improved function in normal populations, the preclusion of 
induced cytotoxicity by the pre-application of PEG-catalase demonstrates the opposite 
and detrimental effect hydrogen peroxide has within the MDSL cell.  
 In order to determine which pathways may be regulated by MnP treatment within 
the MDSL cell line, we performed an ELISA assay that contained binding motifs for 
several redox sensitive transcription factors. We found that MnP treatment results in AP-
1 pathway activation (Figure 3.4A). These results were confirmed by the observation of 
increased phosphorylation of several members of the MAP-kinase cascade, including N-
terminal jun kinase (Figure 3.4B). This versatile group of transcription factors is 
composed of Fos and Jun proteins that dimerize with various AP-1 partners, including 
themselves, before DNA binding is activated (104, 187, 188). To elucidate which 
member may be involved, we performed a series of immunoprecipitation experiments 
across combinations of c-Jun, JunB, and JunD as no Fos proteins could be detected. From 
these co-immunoprecipitations we determined the potential for JunB homodimerization 
and subsequently confirmed the consistent activation of JunB after MnP treatment 
(Figure 3.4C-D). Moreover, this activation was further confirmed by a DNA binding 
assay utilizing a 5’-biotinylated oligonucleotide containing the AP-1 consensus DNA 
binding sequence. Here, MnP treatment resulted in a greater pulldown of JunB in 
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comparison to vehicle control confirming the MnP induced activation of JunB DNA 
binding activity (Figure 3.4E). 
 The regulation and activation of the AP-1 transcription factors has been well 
defined by JNK phosphorylation of c-jun; however, the lack of JNK docking sites and 
alternative outcomes after phosphorylation with any other jun family members has led to 
the identification of redox regulatory factors that interact with Jun proteins. Ref-1, 
identified in the early 1990’s as a dual function protein, demonstrates strong redox 
activity towards the AP-1 family proteins (238, 239, 242). Because of the alterations to 
the intracellular redox environment introduced by MnP treatment, we investigated the 
potential involvement of Ref-1 contributions to JunB activation. Upon treatment with 
MnP we found that Ref-1 does co-immunoprecipitate with JunB in comparison to vehicle 
control (Figure 3.5A-B). To confirm this interaction, we performed the reverse 
immunoprecipitation and, in fact, JunB does co-precipitate with the Ref-1 pulldown 
(Figure 3.5C-D). These robust and consistent results demonstrate targeted AP-1 
activation differential to normal HSC counterparts.  
 The alteration of the MDSL cell redox environment, the production of 
intracellular H2O2 and the subsequent interaction with Ref-1 strongly suggest that JunB 
is subject to redox regulation via MnP treatment. The DNA binding region of Fos/Jun 
proteins is highly conserved amongst family members. Within this motif, a single 
cysteine reside resides adjacent to basic amino acids that make contact with the DNA 
backbone upon transcriptional activation. There is some evidence that this residue retains 
a diminished pka, potentially making it susceptible to oxidation via H2O2 produced by 
MnP treatment. To investigate this, we utilized the chemical probe, biotin-1,3-
96 
 
cyclopentadione (BP-1), which specifically and faithfully reacts with sulfenic acid 
cysteines that form via H2O2 oxidation (65, 168, 171). Treatment with MnP and 
subsequent incubation with BP-1 allowed for the consistent pulldown of oxidized JunB 
via streptavidin linked beads (Figure 3.6A-B). The clear involvement of both JunB and 
Ref-1 in MnP induced cytotoxicity led us to confirm their implication through individual 
knock downs within the MDSL cell line. However, the slow MDSL cell growth rate and 
the inherent difficulty in transient transfection of suspension cells lead us to a lentiviral 
based approach. We produced lentivirus containing shRNA directed toward JunB and 
Ref-1 and transduced MDSL cell populations individually. Each knockdown cell type 
was selected via FACS analysis using fluorescent tags and was then cultured in selection 
media containing puromycin. This lead to the successful development of 100% 
knockdown positive populations evidenced by the fluorescents tags demonstrated in 
Figure 3.7 A & D (JunB KD-GFP; Fer-1 KD-mCherry). These populations display an 
extremely efficient knockdown, as no detectible protein is found in comparison to equal 
loading of the WT controls (Figure 3.7 B&E). Here, neither individual knockdowns 
display any dose or time dependent cytotoxicity in response to MnP treatment compared 
to the control MDSL parental cell line. These results clearly identify the activation and 
involvement of JunB with Ref-1 in MnP mediated cytotoxicity within the MDSL cell line 
and provide a potential druggable target for future development that is crucial to the 
management of myeloid lineage populations within hematopoietic neoplasms. 
Discussion 
The myelodysplastic syndromes are a diverse set of myeloproliferative disorders 
that have proven to be aggressive and difficult to treat. The MDS phenotype offers a 
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window for the development of therapeutics that may demonstrate the advantage of 
targeting molecular pathways prior to and during malignant transformation. The MDSL 
cell line derived from a patient in the pre-leukemic stage of MDS demonstrates stem and 
progenitor clonal characteristics through the expression of CD34, CD117, CD38, CD45 
and CD33 (173, 174). These cells contain a variety of complex cytogenetic abnormalities 
that contribute to the stem/progenitor dysplastic phenotype (130).  Moreover, these cells 
efficiently engraft into NSG and NSGS mice and demonstrate a latency period of 
engraftment development (NSG, 55-56 days; NSGS, 20-28 days) within the bone marrow 
and spleen before clonal expansion carrying to the peripheral blood, resulting in 
peripheral blood cell suppression. These engraftments do respond to clinically relevant 
dosing regimens of lenalidomide treatment at 25 mg/kg/day, M-F which has improved 
erythropoiesis and T-cell activation in the face of pro-inflammatory cytokine suppression 
(130, 173, 174). Limited access to primary patient samples makes this model an 
important platform for the identification of molecular pathways and novel therapeutics 
that focus on broad treatment of MDS expansion and restoration of normal 
hematopoiesis, rather than individual targeted therapies.  
We have recently identified the manganese porphyrin MnTnBuOE-2-PyP5+ 
(MnP) as a redox active compound that poses no toxicity to normal hematopoietic tissues, 
but, in fact, aids normal hematopoietic function. MnP induced production of hydrogen 
peroxide via metabolism of cellular superoxide results in Nrf2 activation and the 
upregulation of antioxidant defense enzymes that include manganese superoxide 
dismutase, catalase, and glutathione synthesis enzymes. MnP treatment in vitro and in 
vivo results in improved CFC (colony forming cell assay) and CAFC (cobblestone area-
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forming assay) performance, increased LSK frequency, and improved engraftment 
demonstrated by serial bone marrow transplants through tertiary recipients (256). These 
results led us to evaluate MnP effects in the MDSL cell line and resulted in the 
identification of a molecular target within the AP-1 signaling pathway, JunB.  
Treatment of the MDSL cell line with MnP results in a dose dependent increase in 
cyto-toxicity through alteration of the intracellular redox state, demonstrated by a 
decrease in the glutathione based cellular reduction potential and the increase in steady 
state intracellular hydrogen peroxide concentrations. This alteration of the MDSL cellular 
redox state, while somewhat mild, is significant because it ultimately results in AP-1 
transcriptional activation through JunB oxidation and interaction with Ref-1. First 
identified by Xanthoudakis and Curran (238-241), Ref-1 (APE-1) is an endonuclease 
involved in various DNA repair pathways; however, Ref-1 has a dual function that 
involves strong redox regulation of AP-1 family proteins. This function is sufficient to 
result in AP-1 transcriptional activation and has a stronger effect than that of DTT in the 
reduction of oxidized AP-1 proteins (239, 242).  
The immunoprecipitation of JunB after MnP treatment demonstrates in an 
increase in MnP mediated JunB-JunB dimer formation as well as an increase in JunB-
Ref-1 interaction. The AP-1 family proteins belong to a family of basic leucine zipper 
transcription factors composed of Fos-Jun family members. To date several elegant 
crystal structure studies have characterized the DNA complex formation and the redox 
regulation of Fos-Jun activity (70, 84, 249). These transcription factors contain a highly 
conserved DNA binding region that contains an essential cysteine residue (Cys 285; bZIP 
cysteine) surrounded by the basic amino acids responsible for contacting the DNA 
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backbone upon transcriptional activation. These residues have the potential to withdraw 
electron density from the bZIP cysteine, in effect lowering the cysteinyl pKa. This allows 
for the formation of the thiolate anion cysteine, which can not only repel the DNA 
backbone preventing transcriptional activation, but also makes this residue susceptible to 
oxidation. Interestingly, in all of these studies, the authors note that cys 285 must be 
mutated to serine in order to first, prevent protein oxidation, and second, to allow protein-
DNA complex formation (70, 84, 249). While the most well characterized dimer of the 
AP-1 family c-Jun-c-Jun in known to be regulated by the activity of N-terminal Jun 
Kinase (JNK), c-Jun as well as other members of the AP-1 family are subject to redox 
regulation (239, 240). In MDSL cells we have found that MnP treatment results in redox 
regulated JunB activation, evidenced by MnP mediated JunB-DNA complex formation 
and the MnP mediated formation of sulfenic acid cysteine within JunB via oxidation by 
hydrogen peroxide, as demonstrated by JunB reaction with BP-1. We believe that MnP 
mediated oxidation of JunB then recruits and requires Ref-1 mediated reduction of the 
JunB cysteine residue. Individual lentiviral mediated knock down of both JunB and Ref-1 
resulted in the protection of MDSL cells from MnP-induced cytotoxicity, further 
confirming the importance of these mechanistic targets for MnP treatment of MDSL 
cells.  
The finding that MnP can induce JunB activation via redox control is potentially 
very significant for the advancement of MDS therapy, as JunB has previously been 
identified as a major contributor to the control of myeloid lineage cellular compartments. 
Not only does JunB control the expansion of granulocyte-macrophage populations 
through upregulation of p16INK4a, p18, and p57 JunB deficient mice develop significant 
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myeloproliferative disorders that closely resemble myelodysplastic syndromes (99, 156-
159, 177). Wherein, loss of JunB expression leads to the loss of cell cycle control and 
increases the proliferative capacity of LT-HSC without affecting their self-renewal 
capacity. Thus, JunB inactivation may lead to clonal expansion without resulting in 
complete bone marrow failure much like the transformation of a myeloproliferative 
disorder to a malignant leukemia. Notably, MnP has demonstrated the ability to regulate 
p16, which is an important cell cycle regulator controlling myeloid expansion and key 
targets of JunB transcription (185, 231). MnP versatility as a therapeutic is further 
supported by the recent discovery that the AP-1 transcription factors preferentially bind 
to hemimethylated consensus DNA sequences (84). Taken together, these facets of MnP 
activity and AP-1 function provide potentially safe therapies for individuals who are 
refractory to first line treatments of hypomethylating agents as well as those who may not 
tolerate aggressive AML therapies or allogenic bone marrow transplants.  
Future efforts should be directed at further characterization of MnP control over AP-1 
activation. The stable JunB and Ref-1 cell lines described here may be used to identify 
MnP transcriptional regulation as well as key JunB targets. These cell lines also present 
the opportunity to further quantify MnP mediated JunB oxidation. Although several 
studies speculate a decreased cysteinyl pKa within the Jun DNA binding region, a pH 
dependent DNA binding approach may narrow in on the exact nature of Jun redox 
sensitivity. 
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Figure 3.1 MnP toxicity in normal and malignant cells 
A) MDSL dose-response curve was generated within a 95% confidence interval by treating 
MDSL cells at various MnP concentrations for 48 hours and cytotoxicity evaluated by MTT 
assay. B) MDSL cells were treated with MnP for 24 hours and potential differentiation was 
observed by flow cytometry. C-E) Normal human bone marrow cells were treated with MnP for 
24 hours and were subsequently evaluated for viability by PI staining and stem marker evaluation 
by flowcytometry. Statistical analysis represents n=3 by one-way ANOVA with Tukey’s post hoc 
analysis, error presented as SEM. * p<0.05, ** p<0.001, *** p<0.0001, **** p<0.00001 
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Table 3.1 MnP Effect on Intracellular pH 
Table 3.2 MnP Effect on Cellular Volume 
Volume 
Table 3.3 MnP Effect on Intracellular Glutathione Concentrations 
Tables 3.1-3. 3) 3.1) Indicates the intracellular pH levels after MnP treatment in MDSL cells 
measured by BCECF fluorescence. 3.2) shows average MDSL cellular diameter after MnP 
treatment. 3.3) Intracellular molar concentrations calculated using quantitative LC-MS/MS 
results and cell volume calculated from measured diameters, after MnP treatment. 
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Figure 3.2 MnP effect on MDSL cellular reduction potential 
Glutathione half-cell reduction potentials in vehicle and MnP 
treated (20 μM) cells. Error is presented as SEM, n=3. 
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Figure 3.3 MnP effect on intracellular H2O2  
A) Intracellular steady state levels of hydrogen peroxide after 20 μM MnP treatment for 1 
hour measured by catalase inhibition. B) Catalase activity in MDSL cells after MnP treatment 
at time zero (no catalase inhibition). C) MTT assay for MDSL cells treated with MnP and/or 
PEG-CAT. N=3, error presented as SEM, statistical analysis done by two-way ANOVA with 
Tukey’s post hoc testing, or t-test where appropriate. * p<0.05. 
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Figure 3.4 MnP effect on transcriptional activation 
A) Transcriptional ELISA array analysis of nuclear extracts from vehicle and MnP treated 
MDSL cells (data shown as fold change from vehicle control, n=3). B) Western blot 
analysis of MAPK pathway activation by detection with phosphor-antibodies after MnP 
treatment. C) Immunoprecipitation followed by immunoblot analysis for activation of AP-
1 family transcription factors. D) Quantitation of JunB immunoprecipitation after vehicle 
or MnP treatment in MDSL cells. E) Biotin-streptavidin DNA pulldown assay of nuclear 
extract from MDSL cells treated with either vehicle or MnP for 1 hour. Statistical analysis 
completed by two-way ANOVA and Tukey’s post hoc test or t-test where appropriate; 
*p<0.05.  
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Figure 3.5 MnP induces JunB interaction with Ref-1 
A-D) Forward and reverse co-immunoprecipitation of JunB and Ref-1 in MDSL cells after 
vehicle or MnP treatment for one hour. Quantitation n=3, statistical analysis done by t-test; 
*p<0.05, **p<0.001. 
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Figure 3.6 MnP induces oxidation of JunB 
A-B) Biotin-streptavidin pull down of JunB with BP-1 reacted with JunB sulfenic acid 
form cysteine after vehicle or MnP treatment. Quantitation n=3, error presented as standard 
deviation, statistical analysis completed by t-test; *p<0.05. 
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Figure 3.7 JunB and Ref-1 mediate MnP induced MDSL cell cytotoxicity 
A&D) Flow cytometry analysis of WT and JunB (top) or Ref-1 (bottom) knockdown 
populations for reporter tag. B&E) Western blot analysis for JunB (top) and Ref-1 
(bottom) protein concentrations in WT control vs knockdown MDSL cells. C&F) MTT 
assay after MnP treatment for JunB (top) and Ref-1 knockdown cells compared to WT 
controls. Statistical analysis completed by two-way ANOVA and Tukey’s post hoc test, 
n=3 error presented as SEM **p<0.001. 
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Chapter Four: Targeting the Chemo-resistant Malignant Phenotype Through 
Manipulation of the Intracellular Redox Environment 
Introduction 
Cancer treatments which exploit variations between normal and malignant redox 
states are gaining validation through pre-clinical models as well as clinical trials. These 
therapies include the use of pharmacological doses of ascorbate alone and in concert with 
ionizing radiation, the application of polyphenyls, and the use of manganese porphyrins 
(93, 126, 181, 210). Commandeering heightened cancer cell metabolism to produce 
intracellular hydrogen peroxide concentrations detrimental to cancer cell survival are at 
the heart of these therapeutic strategies. For example, in a pre-clinical glioblastoma 
model, ascorbate treatment produces hydrogen peroxide that results in the disruption of 
iron-sulfur metabolism leading to an increase in labile iron pools causing oxidative 
damage at several cellular levels. Natural compounds such as β-phenylethyl 
isothiocyanate (PEITC) have been effective in the treatment of Gleevec resistant CML 
models that express the Bcr-Abl fusion protein. These studies are centered on the ROS 
induced oxidative degradation of Bcr-Abl resulting from the generation of hydrogen 
peroxide (253). Several manganese porphyrin compounds have recently demonstrated 
cytotoxicity within different cancer models, including inflammatory breast cancer as well 
as lymphoma models (15, 93, 210, 211). Reduction of metabolic superoxide to hydrogen 
peroxide is the critical step in Mn-porphyrin based therapeutic approaches, one that can 
be enhanced through co-treatment with ascorbate. 
The current state of redox based therapeutic strategies relies heavily on malignant 
cell sensitivity to peroxide generators. However, the very alterations that expose 
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malignant cell types to redox based therapeutics may also provide ingrained defense 
mechanisms that confer chemo-resistance to promising therapies that not only kill cancer 
cells but protect off target normal tissues. The continued development and success of 
redox therapy requires the consideration of approaches that circumvent developed or 
innate chemo-resistant phenotypes. To date, potential therapies that demonstrate a robust 
capacity to generate hydrogen peroxide predominantly describe alteration of the 
malignant cell redox state through the depletion of cellular glutathione pools. While most 
cell types harbor GSH concentrations in the 1-10 mM range, the extensive study of GSH 
has revealed its clear importance to normal cellular function and redox maintenance. As 
the dominating reducing species within the cell, researchers have found the relationship 
of the GSH-GSSG redox couple with Gibb’s free energy, expressed through the Nernst 
equation, as a useful tool for the examination of the cellular redox state (178). Beautifully 
characterized by Schafer and Buettner (178), we can define various physiological 
parameters along with the absolute concentration of the oxidized (GSSG) and reduced 
(GSH) species to quantitate outcome responses to qualitative manipulations and cellular 
states.  
The cysteinyl pKa of GSH (~8.9) makes it is an average reducing agent alone, yet 
we have previously thought that the high intracellular concentration of GSH could 
compensate, making it a reducing mop that can neutralize oxidative threats that befall the 
cellular milieu. We now know that high GSH concentrations also maintain the function of 
glutathione metabolizing enzymes, such as glutathione S-transferases and glutaredoxins 
that detoxify xenobiotics and reversibly modify protein thiols, as well as the glutathione 
peroxidases that efficiently remove hydrogen peroxide (48). While considering only the 
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“buffer” capacity of GSH is not enough to accurately describe the complex glutathione 
system, pairing the quantitation of the GSH-GSSG half-cell reduction potential with 
various enzyme kinetic data may help our incomplete understanding of how the 
glutathione redox pair is utilized to manage the cellular redox state. 
Glutathione’s diverse importance and versatility make the redox couple a prime 
target for the development of both therapeutic strategies as well as chemo-resistant 
phenotypes. It is no surprise then, that some cancers may utilize high intracellular 
concentrations of GSH to demonstrate chemo-resistance against peroxide generating 
therapies, as elevated GSH within malignant populations is a well-established 
phenomenon. However, simply targeting overall cellular glutathione concentrations is an 
undesirable approach, for not only have cancer cells shown the ability to survive with low 
GSH concentrations, the level of depletion required for a desired effect delivers too many 
negative off-target outcomes. However, we may find ways to manipulate glutathione 
metabolism and utilization for therapeutic benefit. Because the ability to replenish GSH 
after oxidative metabolism is so important to the function of glutathione utilization, 
glutathione reductase activity is a key determinant for the maintenance of the GSH-GSSG 
ratio.  
GR is an oxido-reductase that completes two half reactions utilizing two NADPH 
molecules for sequential reduction of an FAD domain which transfers electrons to active 
site cysteines that complete the reduction of two molecules of glutathione disulfide. GR is 
highly expressed in a wide variety of tissues and cancers, particularly in those pertaining 
to the hemopoietic compartment. Thus, while targeting glutathione synthesis directly may 
be too toxic to normal tissues, efficient inhibition of GR can potentially be utilized not 
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only to enhance redox based therapies, but overcome chemo-resistant phenotypes in 
which glutathione metabolism is employed to protect the malignant cell from excess 
peroxide generation. 
We have recently found that the Mn-porphyrin MnTnBuOE mediated production 
of hydrogen peroxide poses no toxicity to normal tissues but actually enhances normal 
stem cell function through the up-regulation of Nrf2 activity and increase in stem cell 
antioxidant capacity. Conversely, others have reported its efficacy as an anti-cancer 
agent, we have tested this compound’s cytotoxicity across several malignant models 
derived from the hematopoietic compartment. Evaluation of several factors that 
contribute to the management of the cellular redox state, in fact, reveal glutathione 
reductase activity and the ability to perpetually reduce oxidized glutathione as a mediator 
of chemo-resistance to MnTnBuOE treatment. Herein we investigate the principal of 
targeting the cellular redox state as a means of circumventing chemoresistance to redox 
active compounds. 
Materials and Methods 
Cell culture and treatments 
K562 cells were cultured in IMDM media (ATCC; Manassas, VA) containing 1% 
penicillin/streptomycin (Life Technologies; Grand Island, NY) and 10% FBS (GE 
Healthcare; Pittsburgh, PA). HL-60 and MDSL cell lines were cultured in IMDM media 
containing 1x penicillin/streptomycin and 20% FBS. MDSL cell culture media was 
supplemented with 15 ng/mL human IL-3 (Peprotech; Rocky Hill, NJ). All cultures were 
kept in a humid environment at 37° C supplemented with 5% CO2. Where indicated cells 
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were treated with 50 μM buthionine-sulfoximine (BSO) (Sigma Aldrich; St. Louis, MO) 
for 12-16 hours overnight. Glutathione reductase inhibition was achieved via 12-16 hours 
overnight treatment with 7 μM carmustine (Enzo Life Sciences; Farmingdale, NY). MnP 
was synthesized and characterized by Dr. Ines Batinic-Haberle and her colleagues at 
Duke University School of Medicine; Durham, NC. Where indicated, MnP treatment was 
combined with BSO and carmustine after overnight pre-treatments at indicated 
concentrations. MnP treatment alone was accomplished by supplementing culture 
medium with drug at indicated concentrations and durations. Where indicated cells were 
treated with PEG-Catalase (Sigma Aldrich, St. Louis, MO) at a concentration of 
approximately 80 Units/cell for 12-16 hours overnight. 
Cell viability 
Cell viability was determined by two different assays. First viability was 
determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) assay. Cells were plated at a density of 100,000-200,000 cells/mL and were 
incubated with indicated drug treatments for 48 hours. At the time of analysis, samples 
were collected and transferred to 5 mL round bottom polystyrene tubes (Corning; 
Harrodsburg, KY), pelleted via centrifugation at 1300 rpm for 5 minutes and 
subsequently washed twice with sterile PBS. Samples were then resuspened in DMEM 
media containing no phenol-red supplemented with 0.5 mg/mL MTT reagent. Cells were 
re-plated in a 96 well plate at 30,000 cells/well and incubated at 37° C (5% CO2) for 3.5 
hours. Cells were then lysed with 1:1 (v/v) DMSO and isopropanol, then incubated for 25 
minutes in the dark. Absorbance was then measured at 560 and 690 nm. Additionally, 
cell viability was determined by flow cytometry. The number of cells within a viable gate 
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separated from fragmented cellular debris was set in a dot-plot by the determination of 
forward scatter vs side scatter. The number of cells in this gate divided by the total 
number of events measured was taken as the percent of viable cells. 
Glutathione quantitation and calculation of half-cell reduction potential 
We have previously summarized the development, validation, and implementation 
of simultaneous GSH and GSSG quantitation via LC-MS/MS. Briefly, treated samples 
and controls were transferred, at 30,000 cells per sample, to 5 mL round bottom 
polystyrene centrifuge tubes and were subsequently pelleted at 1300 rpm for 5 minutes. 
Supernatants were vacuum aspirated and cells were subsequently lysed in an ice cold 2% 
TCA solution containing 1 mM EDTA, vortexed for 30 seconds and incubated on ice for 
15 min. Samples were then vortexed a second time and were further incubated on ice for 
15 minutes. Cellular debris was then pelleted at 4,000 x g for 10 minutes and sample pH 
was adjusted to 2.0 prior to LC-MS/MS analysis. Samples concentrations were calculated 
based on external standard curve analysis with the linear form 𝑦 = 𝑚𝑥 + 𝑏. Sample 
concentrations in ng/mL were converted to moles of analyte using the molar mass for 
glutathione and glutathione disulfide. This conversion was then used to calculate the 
molar analyte concentrations per cell after cellular volume determination.  
Cellular diameter was determined via the Coulter principal and electrical 
impedance. This was accomplished with a Scepter cell counter (Millipore Sigma; 
Burlington, MA). Samples were collected, washed twice with PBS and analyzed with a 
40 μm sensor. Average cellular diameters were then used in the equation for the volume 
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of sphere, 𝑉 =
4
3
𝜋𝑟3, to calculate cellular volume. This value was used to divide analyte 
concentrations (moles) resulting in cellular molar analyte concentrations.  
Molar concentrations were then used to calculate the glutathione-based half-cell 
reduction potential at 25°C, pH 7.0 as summarized by Schaffer and Buettner (178). 
 𝐸ℎ𝑐 = −240 − (
59.1
2
) log (
[𝐺𝑆𝐻]2 
[𝐺𝑆𝑆𝐺]
) 
Western blotting 
Western blots were prepared as follows. 3.0 x 105 cells were lysed in standard ice 
cold RIPA buffer with protease and phosphatase inhibitors for 30 minutes on ice. Cellular 
debris was removed by centrifugation at 10,000 rpm for 10 minutes. Equal amounts of 
protein were then diluted with 2x Laemmli sample buffer (Bio-Rad Laboratories; 
Hercules, CA) and boiled at 95°C for 5 minutes. Samples were then resolved in a 10% 
SDS-PAGE gel at 160 V for 90 minutes. Proteins were transferred to a nitrocellulose 
membrane at 100 V for 60 minutes. Membranes were blocked with 5% milk in TBST 
(pH=7.4) for 60 minutes before the indicated primary antibodies were administered and 
incubated for 16 hours, overnight at 4°C. Membranes were washed with TBST and 
incubated with HRP-conjugated secondary antibodies for 60 minutes prior to detection 
with ECL reagent (GE Healthcare; Pittsburgh, PA) on x-ray film (Denville Scientific; 
Holliston, MA). Protein quantitation was determined using image J software (NIH; 
Bethesda, MD) by band intensity normalization to β-actin controls (n=3). 
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Enzyme activity determination 
Glutathione reductase activity was measured with the OxiSelect kit from Cell 
Biolabs. This assay utilizes consumption of NADPH in the presence of excess 
glutathione disulfide to induce the interaction of reduced glutathione with a chromogen, 
producing a colorimetric response that absorbs at 405 nm. Enzyme activity was measured 
according to Cell Biolabs protocol. Treated samples and controls were collected and 
washed twice with PBS before lysis in 1X assay buffer via 3 rounds of sonication in an 
ice-cold water bath at 3 minutes per round with 30 second breaks between rounds for 
vortex mixing. Samples were then combined with NADPH and chromogen assay 
reagents in a 96 well plate. Glutathione disulfide was then added immediately prior to 
analysis by kinetic measurement of absorbance at 405 nm at 1 minute intervals for 10 
minutes. A standard curve with known concentrations of glutathione reductase enzyme 
was evaluated simultaneous to the unknown samples. Background samples with no 
glutathione disulfide present were subtracted from standards and samples. The average of 
(n=3) slope was determined and used to calculate unknown glutathione reductase activity 
in relation to the standard curve. 
Total glutathione peroxidase activity was determined by a reaction coupled with 
glutathione reductase and the consumption of NADPH evaluated by a decrease in 
absorbance at 340 nm. This assay was accomplished with the Glutathione Peroxidase 
assay kit obtained from Cayman Chemical; Ann Arbor, MI. The GPx assay was carried 
out according to Cayman Chemical protocol. Samples and Controls were lysed in sample 
buffer (50 mM Tris-HCl, pH 7.6, 5 mM EDTA, 1 mg/mL BSA) by sonication in an ice 
cold water bath for 3 rounds of 3 minutes per round with 30 second breaks for vortex 
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mixing. Samples were combined with a co-substrate mixture and assay buffer (50 mM 
Tris-HCl, pH 7.6, 5 mM EDTA) and Cumene Hydroperoxide was added immediately 
prior to measuring absorbance at 340 nm at 1 minute intervals for 10 minutes. A non-
enzymatic background well was used to account for background absorbance loss and a 
positive control well containing bovine erythrocyte GPx was used to confirm assay 
activity. Two points of the absorbance curve were used to determine activity. 
 𝐺𝑃𝑥 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  (
𝛥𝐴340/𝑚𝑖𝑛
0.00373 𝜇𝑀−1
) ∗ (
0.19 𝑚𝐿
0.02 𝑚𝐿
) 
Measurement of catalase activity has been previously described (227). Briefly, 
samples and controls were plated in 6 well plates, treated with 20 mM 3-aminotriazol 
(Sigma Aldrich; St. Louis, MO) and subsequently harvested at 0, 5, 15, 30, 45, and 60 
minutes. Cells were washed and subsequently lysed in in 250 uL of 50 mM phosphate 
buffer pH 7.0 via sonication; 500 uL of 30 mM H2O2 in phosphate buffer was added to 
1.0 mL of sample and the loss of absorbance at 240 nm was observed at 15 second 
intervals for 2 minutes. The 0 time point was used to determine the first order rate 
constant for catalase via the loss of H2O2.   
ROS determination 
General cellular ROS and the presence of H2O2 were determined via mean 
fluorescence of  H2DCFDA (Invitrogen; Waltham, MA). Pre-treatment of samples with 
carmustine or PEG-Catalase was completed as indicated. Samples were then collected in 
5 mL polystyrene round bottom tubes and were washed twice with PBS pH 7.4. Samples 
were then resuspended in a 20 μg/mL solution of H2DCFDA or carboxy-DCFDA in 
PBS, pH 7.4 and incubated in the dark at 37°C for 30 minutes. H2DCFDA and carboxy-
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DCFDA solutions were then removed and samples were washed twice with PBS and 
resuspended in complete culture medium without phenol red, containing either vehicle 
control or 30 μM MnP. Samples were then incubated for 3 hours in the dark at 37°C, 5% 
CO2. Media containing drug was then removed and samples were washed twice with 
PBS prior to analysis by flow cytometery. Fluorescence was measured on a LSR II (BD 
Biosciences; Franklin Lakes, NJ) with ex 488 nm, em 525 nm. 
siRNA transfection 
Transient knock down of glutathione reductase was achieved via siRNA 
transfection. For each transfection, 0.75 μg of control or GR siRNA was diluted in 100 
μL of transfection medium. Separately, 6 μL of transfection reagent was diluted in 100 
μL of transfection medium. Media containing duplex siRNA was then slowly added to 
the transfection reagent diluent dropwise. This solution was gently mixed and incubated 
at room temperature for 30 minutes. The transfection complex was then diluted to 1 mL 
and was subsequently used to gently suspend 5.0 x 105 cells which were then aspirated 
into a single well of a 6 well plate. Transfections were then incubated for 8 hours at 37°C, 
5% CO2 after which 1.0 mL of 2x complete growth medium was added to the 
transfections prior to incubation for an additional 24 hours. Cells were then cultured 
normally for 48 hours at which time they were evaluated for glutathione reductase 
expression via western blot or used for experimental purposes.     
Statistics 
 Statistical analysis for immunoblotting comparing band intensity between 
treatment and control groups for at least three replicate experiments was completed via t-
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test, significance is reported at p<0.05. Cell viability containing multiple drug 
concentrations of a single test group were completed by one-way ANOVA and those with 
multiple test groups were completed by two-way ANOVA, with post hoc evaluation. 
Enzyme activity for multiple groups was evaluated by one-way ANOVA with post hoc 
evaluation. Analyte and viability measurements for multiple drug treatment populations 
were evaluated by two-way ANOVA with post hoc testing. siRNA transfections were 
evaluated in comparison to control siRNA, n=3. All measurements for analytes, ROS, 
and viability were completed in triplicate for each group. Unless otherwise stated, all 
other error is presented as the standard error of the mean (SEM) derived from at least 
three experimental replicates containing multiple measurements for each group. 
Results 
 We set out to examine factors within the K562 redox environment in comparison to 
others that may influence this treatment resistance. Since there is no single element of the cellular 
redox environment that is an agreed upon marker for total redox status, we evaluated several 
factors that are crucial to the management of oxidative stress. Simple analysis of enzyme 
expression provided immediate clear targets that may be inducing chemo-resistance to H2O2 
generated by MnP treatment. By comparison, the K562 cell line expresses high protein levels of 
MnSOD, glutathione synthesis enzymes GCLG and GCLM, as well as high levels of glutathione 
reductase (GR). Conversly the K562 cells demonstrate very low protein expression levels of 
catalase and glutathione peroxidase-1, the front line enzymes utilized to metabolize hydrogen 
peroxide (Figure 4.1A-F). This indicates that the resistant cell line utilizes another mechanism to 
cope with H2O2 produced by high levels of MnSOD from metabolic superoxide.  
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Because several isoforms of antioxidant enzymes exist and expression levels do not 
always dictate catalytic efficiency, we went on to evaluate enzyme activity as well as the half-cell 
reduction potentials for glutathione to gain further insight into the onset of the resistant 
phenotype. We found that, indeed, the K562 cells demonstrate lower catalase and very low 
relative GPx activity levels (Figure 4.3A-B). However, they demonstrate very high levels of GR 
activity as well as a highly reduced glutathione reduction potential in comparison to not only the 
normal human bone marrow controls but to other malignant cell types (Figure 4.3A-D). This 
indicates that constant glutathione synthesis, metabolism, and turnover by glutathione reductase 
works in combination to maintain a highly reduced environment in the face of high metabolic 
stress that accompanies the heightened K562 growth rate (18-24 hr).  
 It is possible that highly reduced glutathione pools impart resistance to MnP treatment. 
With this in mind, we pretreated K562 cells with BSO for 12-16 hours at 0.05 mM to inhibit 
glutathione synthesis. Indeed this induced a significant depletion of reduced intracellular 
glutathione (approximately 90%) and diminished glutathione disulfide levels to undetecTable 
levels (Figure 4.4A-B). Interestingly, this concentration had a negligible effect on K562 cell 
viability alone; however, combination with MnP induced a significant dose dependent cytotoxic 
response not previously observed (Figure 4.4C).  
 While BSO has been investigated in the past, the off-target damage to normal HSC 
glutathione pools is potentially too great to consider, thus we looked to exploit an alternative 
portion of the glutathione metabolism pathway. The elevated expression and activity levels of GR 
indicate that its function may be important to sustain K562 proliferation. As such, we used a GR 
inhibitor (carmustine) in combination with MnP to determine the effects on the cellular redox 
environment and potential response to redox based therapy. Carmustine (GR-I) was titrated and 
the highest non-toxic concentration (7 μM) was chosen for combination treatment with MnP (data 
not shown).  Initial studies demonstrate efficient inhibition of glutathione reductase (over 50%, 
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Figure 4.5B) with a 12-16 hour overnight treatment. This results in a significant alteration of the 
2GSH/GSSG ratio, which dictates the cellular reduction potential, through the accumulation of 
oxidized glutathione and elevated reduced glutathione due to synthesis (Figure 4.5A, C-E). 
Additionally, this combination treatment induced a significant amount of DCF fluorescence in 
comparison to any treatment alone. This high fluorescence level was predominantly quenched 
through the pre-treatment with PEG-catalase, indicating that the major oxidative species produced 
by combination glutathione reductase inhibition and MnP is in fact hydrogen peroxide (Figure 
4.6). In concert with this production of H2O2, we observed a significant decrease in K562 cell 
viability, demonstrated by increased cell fragmentation and loss of viable scatter. Importantly, 
this loss of viability was rescued by pre-treatment with PEG-catalase, demonstrating H2O2 as the 
culprit of cytotoxicity (Figure 4.7A-B). This indicates that glutathione reductase is a potential 
mediator of chemo-resistance to redox therapeutics and potentially to others as well.  
 To confirm GR’s essential role in this phenotype, we took advantage of the aggressive 
K562 cell nature and were able to perform transient siRNA knockdown of GR (Figure 4.8A). Just 
as we observed with the inhibition of GR function, knockdown of GR resulted in a significant 
alteration to the 2GSH/GSSG ratio (Figure 4.8C-E) and allowed for significant MnP mediated 
increase in DCF fluorescence that was, again, quenched by pre-treatment with exogenous catalase 
(Figure 4.8F-G). Similarly, knockdown combined MnP treatment induced a significant loss of 
viable scatter that was recovered through the addition of catalase (Figure 4.9A-B). These results 
confirm the involvement and importance of GR in the potential development and propagation of 
chemo-resistance, particularly to redox active compounds. Overcoming chemo-resistance to 
alternative therapies has an important role for the successful development of new therapeutics and 
the ability to target glutathione metabolism outside of glutathione synthesis will aid future drug 
development and hopefully, successful treatment paradigms. 
 
122 
 
Discussion 
Redox based therapeutics such as pharmacological ascorbate offer alternative treatment 
options for aggressive cancers in patients who develop resistance or do not initially respond to the 
standard of care options (181, 182). These drugs have a promising future, particularly within the 
field of hematopoietic cancers because they may differentially target the malignant redox 
environment while protecting off target tissues. However, the attributes of the redox environment 
that lend themselves to some treatments may also develop resistant mechanisms in the future. 
Successful and continued therapeutic development requires that we address such issues. We have 
tested the novel manganese porphyrin MnTnBuOE against three malignant models within the 
myeloid lineage and found varying cytotoxic results. The AML and MDS model cell lines HL-60 
and MDSL both respond to MnP treatment at increasing doses; however, we have found that the 
Gleevec resistant CML blast model K562 cells does not respond to MnP at similar concentrations 
(Figure 4.1). 
Continued development of cancer therapeutics which target the malignant cell 
redox state through the production of H2O2 is a promising avenue for novel treatments 
that are both safe and effective. The success of these treatments depends on the 
consideration of complex scenarios that include the development or existence of 
phenotypes refractory to alteration of the intracellular redox milieu. This includes cancer 
cell utilization of the abundant glutathione pool which participates in a complex and 
necessary landscape of oxidoreductase modifications and reactions. Because the 
maintenance of cellular glutathione at some level is vital to the survival and growth of 
normal, off target tissues, targeting the glutathione system for therapeutic benefit has 
been difficult. Although there is some recent evidence to suggest that targeting 
glutathione synthesis in combination with chemotherapy may improve treatment 
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outcomes in multiple myeloma models, the off-target effects of this combination may still 
prove to be too harsh (203). For these reasons, we set out to determine the effects of the 
MnSOD mimetic MnTnBuOE.  
We have recently found that this compound alters the cellular redox state via 
production of H2O2, yet this increases stem cell number and improves HSC function 
through the upregulation of Nrf2 activation (256). This demonstrates the potential for the 
safe chemotherapeutic intervention of malignant phenotypes. Discovering variable 
cytotoxic sensitivity in several cancerous cell lines derived from the myeloid lineage, we 
went on to further access the redox factors that influence sensitivity to this H2O2 
generator. The presentation of chemo-resistance to MnTnBuOE in the K562 cell line 
compared to MDSL and HL-60 cell lines led to the discovery that the K562 cells 
demonstrate heightened antioxidant capacity in the form of elevated GSH levels and 
elevated cellular reduction potential that results from heightened glutathione reductase 
activity. While MnTnBuOE induced K562 cytotoxicity via BSO pre-treatment 
demonstrates the importance of the glutathione system to the chemo-resistant phenotype, 
the inhibition of glutathione reductase and the alteration of the cellular reduction potential 
presents glutathione homeostasis as a potential target to circumvent this resistance. Both 
the inhibition of GR activity and the knock down of GR protein expression results in the 
production of H2O2 when paired with MnTnBuOE treatment, as evidenced by quenching 
DCF fluorescence through the application of exogenous catalase. Importantly, rescue of 
MnTnBuOE mediated H2O2 production via catalase also rescues K562 cell viability. This 
indicates that targeting glutathione metabolism through glutathione reductase activity 
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rather than glutathione synthesis or overall glutathione concentrations offers an 
alternative approach to target redox mediated chemotherapeutic resistance.  
Because a highly efficient ability to reduce oxidized glutathione is an essential 
component of the resistance phenotype, while the “glutathione addiction” typically found 
in various cancers may be present, inhibition of synthesis and drastic depletion of 
glutathione pools is not required for induction of cancer cell cytotoxicity. This presents 
potential alternative approaches for targeting the glutathione system that may increase the 
safety and efficacy of chemotherapeutic treatment as well as bringing interesting 
questions concerning manipulation of the cancer cell redox state. For example, within the 
bone marrow compartment, the location and quiescence of the normal HSC offer 
protection and defense against oxidative insult. This combination may also mean that 
latent HSC’s may not require extremely high glutathione reductase activity to maintain 
reduced glutathione pools as well as a reduced cellular redox state. By contrast, the 
relative inhibition of GR in cancer cells may be much more detrimental to cell survival. 
Our results indicate that this combined with the H2O2 generator MnTnBuOE may offer 
effective treatment of resistant cancer phenotypes without significantly damaging off-
target tissues. 
The finding that glutathione reductase activity may be targeted to predispose 
chemo-resistant cancer cells to hydrogen peroxide production brings up several 
interesting questions that may not only improve therapeutic approaches but may also help 
clarify our incomplete understanding of glutathione utilization and function. For example, 
the structure-activity relationship of the MnTnBuOE allows for its accumulation in 
subcellular locations, particularly with-in the mitochondria (12, 13, 15). This is 
125 
 
significant as the majority of metabolic superoxide is produced in mitochondria. Studies 
in yeast have revealed that GR has been found in the cytosol and the mitochondrial 
matrix but not in the mitochondrial inner membrane space (IMS). Both the mitochondrial 
matrix and the IMS have very high 2GSH/GSSG ratios, yet while IMS glutathione can be 
replenished from the cytosol, sources of GSH transport into the mitochondrial matrix are 
less apparent (25). Although GSSG can be exported from the matrix to aid in reduction 
potential maintenance, deletion of GR (Grl1) reveals that the IMS can recover normal 
GSH levels after oxidative insult yet the glutathione reduction potential within the 
mitochondrial matrix does not recover. This indicates that GR activity is essential to 
maintain mitochondrial matrix reduction potential (25). Loss of this ability may then 
hamper the activity of glutathione peroxidase, exposing mitochondria to H2O2 production 
through superoxide metabolism. Future investigations should address mitochondrial H2O2 
production via GR inhibition and manganese porphyrin treatment and whether or not this 
signal is significant enough to induce cancer cell death.  
Additionally, our results indicate that not only is the ability to reduce oxidized 
glutathione important but that the actual 2GSH/GSSG redox potential may have some 
effect on overall antioxidant capacity. Future experiments should examine how artificial 
manipulation of the 2GSH/GSSG ratio affects various aspects of the cellular redox state 
and its functional maintenance. Recently, the GSSG mimetic NOV-002, which is a 
racemate of oxidized glutathione and cisplatin (1000:1), has been characterized. This 
compound has demonstrated inhibition of cancer proliferation and survival (49). 
Additionally, NOV-002 has combated cyclophosphamide induced HSPC suppression. 
Within the HL-60 AML model, NOV-002 activates p38 MAPK and JNK, which are 
126 
 
known regulators of HSPC proliferation; however, treatment did not inhibit HL-60 cell 
proliferation (95, 213-215, 222). The cytoprotective effect of this GSSG mimetic may 
offer promising therapeutic developments in the future. As we have shown that GR 
inhibition leads to an accumulation of intracellular GSSG and departure of the 
2GSH/GSSG ratio from the homeostatic “normal” potential within chemo-resistant 
cancer cells, artificial manipulation of GSSG levels with pure oxidized glutathione may 
predispose cancer cells to H2O2 toxicity via co-treatment with an H2O2 generator. The 
effectiveness of this approach may depend on the basal glutathione reduction potential of 
a given cancer phenotype. In this case, the cytoprotective effects of GSSG in normal 
tissues would potentially improve this chemotherapeutic approach. 
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Figure 4.1 MnP cytotoxicity in malignant cells 
48 hour MTT assay for MnP induced cytotoxicity in three different malignant cell 
lines K562, HL-60, and MDSL. Statistical analysis done by two-way ANOVA with 
Tukey’s post hoc test, n=3, error presented as SEM; *p<0.05 
128 
 
 
  Figure 4.2 Antioxidant enzyme expression in malignant cells 
A-F) Antioxidant enzyme expression in three different malignant cell lines. 
Quantitation of n=3, error expressed as standard deviation, statistical test done by 
one-way ANOVA with multiple comparison Tukey’s post hoc test; *p<0.05 
**p<0.001 ***p<0.0001 
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Figure 4.3 Antioxidant enzyme activity and intracellular glutathione reduction potentials 
in malignant cells 
A) Catalase activity in 3 malignant cell lines determined at time 0 of catalase inhibition. B) 
Total glutathione peroxidase activity determined in 3 malignant cell lines. C) Glutathione 
reductase activity in 3 malignant cell lines. D) Glutathione half-cell reduction potentials in 3 
malignant cell lines and compared to normal human bone marrow, determined by LC-MS/MS 
quantitation. Statistical analysis for n=3 determined by ANOVA test with unpaired parameters 
with Tukey’s post hoc testing; error expressed as SEM, *p<0.05, **p<0.001. 
c 
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  Figure 4.4 Glutathione depletion in K562 cells 
A) LC-MS/MS chromatogram of K562 cell lysate depicting quantitation and depletion of 
reduced and oxidized glutathione after treatment with BSO. B) Graphical quantitation of 
GSH after BSO treatment. C) 48 hour MTT assay for K562 cell cytotoxicity after 
combination treatment BSO and MnP. Statistical analysis for n=3 done by two-way 
ANOVA and multiple comparisons to controls with Tukey’s post hoc test or t-test where 
appropriate Error reported as SEM; *p<0.05, **p<0.001.   
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Figure 4.5 Glutathione reductase inhibition in K562 cells 
A) LC-MS/MS chromatogram of K562 cell lysate depicting quantitation of reduced and 
oxidized glutathione after treatment with glutathione reductase inhibitor. B) Graphical 
quantitation of GR activity after inhibition. C-E) Changes in reduced and oxidized 
glutathione concentrations leading to an alteration of the 2GSH/GSSG ratio after 
glutathione reductase inhibition. Statistical analysis for n=3 done by t-test and Error 
reported as SEM; *p<0.05, **p<0.001. 
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  Figure 4.6 GR inhibition allows for MnP induced production of H2O2 
A-B) DCF fluorescence in K562 cells after treatment with GR-I, MnP, GR-
I+MnP+PEG-CAT, A-histogram representation of the geomean DCF fluorescence 
and B-graphical representation. Statistical analysis done for n=3 with two-way 
ANOVA and Tukey’s post hoc test, *p<0.05. **p<0.001. 
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  Figure 4.7 GR inhibition sensitizes K562 cells to MnP induced cytotoxicity 
A) Graphical representation of K562 cell viability after combination treatments with GR-I, 
MnP, and PEG-CAT. B) Representative scatter plots. Statistical analysis done for n=3 with 
two-way ANOVA and Tukey’s post hoc test, *p<0.05. **p<0.001. 
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Figure 4.8 GR knockdown alters K562 cellular redox state 
A-B) Western blot and graphical quantitation of glutathione reductase knockdown in 
K562 cells. C-D) Graphical representation of intracellular glutathione quantitation and 
alteration of glutathione levels after GR knockdown leading to an alteration of the 
2GSH/GSSG ratio. F-G) Histogram and graphical representation of geometric mean DCF 
fluorescence in control and GR knockdown cells after treatment with MnP and PEG-
CAT. Statistical analysis done for n=3 with two-way ANOVA and with Tukey’s post hoc 
test or t-test where appropriate, *p<0.05. 
 
135 
 
  
Figure 4.9 GR knockdown sensitizes K562 cells to MnP induced cytotoxicity 
A) Graphical representation of K562 cell viability after combination treatments with GR 
knockdown, MnP, and PEG-CAT. B) Representative scatter plots. Statistical analysis done for 
n=3 with two-way ANOVA and Tukey’s post hoc test, *p<0.05. **p<0.001.   
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Conclusions 
 Throughout this work I have described the current state and directions of redox 
therapies for hematopoietic diseases, the development and implementation of a novel 
method validated for the analysis of the hematopoietic stem cell and leukemic stem cell 
redox states, and the identification of therapeutic targets that may be utilized for the 
treatment of aggressive neoplastic malignancies as well as the circumvention of chemo-
resistance to develop safer, more effective treatment plans. It is my hope and my intent to 
expand this LC-MS/MS methodology to an ultra-high-pressure liquid chromatography 
platform that will enable much greater sensitivity and allowance for analysis of LT-HSC 
population as well as sub-cellular compartments such as nuclear and mitochondrial 
fractions. This will further our understanding of glutathione’s role in the redox 
environments. As much as we know, our full understanding into the underpinnings of 
glutathione function is far from complete. For example, many cells can survive with low 
glutathione levels, so does this leave GSH-GSSG to be a metabolic co-factor rather than 
an essential reducing agent? Moreover, in the face of oxidative insult, is maintenance of 
the GSH/GSSG reduction potential the most important facet for maintaining global redox 
regulation and does a slight change in electromotive force alter downstream protein and 
pathway function at low but significant levels? 
 The utilization of MnP and identification of molecular targets has of course raised 
many questions in the face of my progress. The first of which is, where in the cell are 
specific redox signals being generated? Transient H2O2 signals may travel through 
various compartments, yet this seems unlikely due to the abundance and efficiency of 
antioxidant enzymes. This gives rise to the potential for the discovery of novel signal 
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mediators that carry out oxidative signaling over longer distances. More focus needs to be 
spent on this aspect as location and strength of signal generation serve as important 
indicators of successful therapeutic development as well as improving global treatments 
that surpass untested “personalized” therapies.  
 The fact that JunB plays a crucial role in myeloid lineage development and 
maturation makes it an attractive therapeutic target. I have found that MnTnBuOE can 
generate H2O2 that results in the transient oxidation of JunB leading to its transcriptional 
activation. While this oxidation and subsequent activation must occur in the nucleus, we 
do not know exactly where the H2O2 signal is initially generated. We know that 
MnTnBuOE is generally targeted to the mitochondria but given the substantial 
antioxidant capacity of the mitochondria, it seems unlikely that H2O2 generated within 
would ever reach the nucleus in high enough concentrations to generate JunB activation. 
If this is the case, future drug design may focus on structure activity relationships that 
target redox cycling therapeutics to the nucleus so that this type of signal may generated 
more efficiently. This approach would aid an increase in drug safety profiles as well as 
combat the potential of limited bioavailability to the bone marrow compartment. 
 The complex nature of the cellular redox milieu offers opportunity in exploitation 
of small differences within basic biology inherent to disease and normal cell types. This 
makes site directed and signal specific redox therapies a promising field for future drug 
discovery.  
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List of Abbreviations: 
ABCG2 = ATP Binding Cassette subfamily G member 2 
ALL = Acute Lymphoblastic Leukemia 
AML = Acute Myeloid Leukemia 
ANT = Adenine Nucleotide Translocase 
AP-1 = Activating Protein-1 
Atm = Ataxia-telangiectsia mutated 
ATP = Adenosine Tri-phosphate 
ATRA = all-trans Retinoic Acid 
BCL-2 = B Cell Lymphoma 2 
BCR-Abl = Breakpoint Cluster Region-Abl Kinase fusion protein 
BM = Bone Marrow 
BSO = Buthionine Sulfoximine 
CAT = Catalase 
CD34 = Cluster of Differentiation Protein 34 
CD38 = Cluster of Differentiation Protein 38 
CD33 = Cluster of Differentiation Protein 33 
CD90 = Cluster of Differentiation Protein 90 
CD133 = Cluster of Differentiation Protein 133 
CD123/IL-3R = Cluster of Differentiation Protein 123/Interleukin-3 Receptor 
CD45RA (PTPRC) = Cluster of Differentiation Protein 45 isofrom A (Protein Tyrosine 
Phosphatase, Receptor Type C isoform A 
CD49f = Cluster of Differentiation Protein 49f (Integrin α6) 
c-Kit/CD117 = Tyrosine Protein Kinase KIT/ Cluster of Differentiation Protein 117 
CLP = Common Lymphoid Progenitor 
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CML = Chronic Myelogenous Leukemia 
CSC = Cancer Stem Cell 
CXCR4 = Chemokine Receptor type 4 
DCF-DA = 2’-7’-dichlorofluorescence diacetate 
Del5q = Myelodysplastic 5q Deletion Syndrome 
DOX/ADR = Doxorubicin/Adriamycin 
DPI = Diphenylene Iodonium 
DZNep = 3-Deazaneplanocin 
ETP = Etoposide 
ETS = E26 Transformation Specific 
FLT3-ITD = FMS like Tyrosine Kinase 3-Internal Tandem Repeat 
Foxo3a = Forkhead box O3a 
GCL = γ-glutamylcysteine synthetase 
GCLC = Glutatmate-cysteine ligase catalytic subunit 
GCLM = Glutatmate-cysteine ligase regulatory subunit 
G-CSF = Granulocyte-Colony Stimulating Factor 
GMP = Granulocyte Macrophage Progenitor 
GPx = Glutathione Peroxidase 
GR = Glutathione Reductase 
GSH = Reduced Glutathione 
GSSG = Oxidized Glutathione 
GST = Glutathione-S-Transferase 
Gy = Gray 
HO
. = Hydroxyl Radical 
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H2O2 = Hydrogen Peroxide 
HOXA9 = Homeobox A9 protein 
HSC = Hematopoietic Stem Cell 
HSPC = Hematopoietic Stem/Progenitor Cell 
IDH1 = Isocitrate Dehydrogenase 1 
IKK2 = IKB Kinase 2 
JNK = Jun N-terminal Kinase 
Ki-67 = MKI67 Antigen KI-67 
LEN = Lenalidomide 
Lin = Lineage 
LMPP = Lymphoid Primed Multipotent Progenitor 
LSC = Leukemic Stem Cell 
LSD1 = Lysine Specific Histone Demethylase 1A 
LSPC = Leukemic Stem/Progenitor Cell 
LTC-IC = Long Term Culture-Initiating Cell 
LSK = Lin-/ Sca-1+/c-Kit+ 
LT-HSC = Long-Term Hematopoietic Stem Cell 
MDS = Myelodysplastic Syndrome 
MEP = Megakaryocyte-Erythroid Progenitor 
MLL/ENL = Mixed Lineage Leukemia/Eleven Nineteen Leukemia 
MM = Multiple Myeloma 
MnTE/MnTE-2-PyP5+ = Mn (III) meso-tetrakis (N-ethylpyridinium-2-yl) porphyrin 
MnTnBuOE/MnTnBuOE-2-PyP5+ = Mn (III) meso-tetrakis(N-(n-
butoxyethyl)pyridinium-2-yl) porphyrin 
MnSODTgH = transgenic mice overexpressing MnSOD 
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MPD = Myeloproliferative Disorder 
MPP = Multipotent Progenitor Cell 
MRP1/ABCC1 = Multidrug Resistant Protein 1/ATP Binding Cassette subfamily C 
member 1 
MTX = Methotrexate 
NAC = N-acetyl-L-cysteine 
NADPH = Nicotinamide Adenine Dinucleotide Phosphate 
NF-kB = Nuclear factor-κB 
NOX = NADPH Oxidase 
Nq01 = NAD(P)H dehydrogenase quinone 1 
Nrf2 = Nuclear factor (erythroid-derived 2)-like 2 
NUP98 = Nuclear Pore Complex Protein 98 
O2 = Molecular Oxygen 
O2
.- = Superoxide 
ONOO- = Peroxynitrite 
PETIC = β-phenylethyl isothiocyanate 
PLM = Piperlongumine 
PRC2 = polycomb-repressive complex-2 
PTEN/PI3K/AKT = Phosphatidylinositol-4,5-bisphosphate 3-kinase/Protein Kinase B 
PTL = Parthenolide 
p38 MAPK = p38 Mitogen Activated Protein Kinase 
p14ARF = p14 Alternate Reading Frame Tumor Suppressor 
p15INK4B = Cyclin Dependent Kinase 4 Inhibitor B 
p16INK4A = Cyclin Dependent Kinase Inhibitor 2A 
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p18INK4C = Cyclin Dependent Kinase 4 Inhibitor C 
p19ARF = Cyclin Dependent Kinase 4/6 Inhibitor 
p21CIP = Cyclin Dependent Kinase Inhibitor 1 
Rho = Rho GTPase 
ROS = Reactive Oxygen Species 
Sca-1 = Stem Cell Antigen 1 
SOD1 = Copper-Zinc Superoxide Dismutase  
SOD2 = Manganese Superoxide Dismutase 
SOD3 = Copper-Zinc Extracellular Superoxide Dismutase 
ST-HSC = Short-Term Hematopoietic Stem Cell 
TBI = Total Body Irradiation 
TCP = trans-2-phenylcyclopropylamine 
TKI = Tyrosine Kinase Inhibitor 
TNF = Tumor Necrosis Factor 
TP53 = Tumor Protein 53 
TRAIL = TNF-related Apoptosis Inducing Ligand 
TXN = Thioredoxin 
TXNIP = Thioredoxin Interacting Protein 
TXNR = Thioredoxin Reductase 
UPC1/3 = Uncoupling Protein 1/3 
53BP1 = p53 Binding Protein 
5FU = Fluorouracil
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